Hypophysitis Research Center

Patients Features

Click the tabs below to read more about the topics:


« Back to Category List

Category: Treatment and Follow-up
386 Matching Records
Pt ID Treatment Mass Reduction Hormone Replacement Follow-Up Follow-Up Years Follow-Up Description
Patient ID Treatment Mass Reduction Hormone Replacement Follow-Up Follow-Up Years Follow-Up Description
160 Hormone replacement None or not specified Just desmopressin Patient began replacement with desmopressin. 2 year later MRI showed persistence of the enlarged pituitary stalk and loss of the posterior pituitary. 3 years after presentation, MRI showed reduction of the enlarged stalk, and still loss of the posterior hyperintense signal. Patient still required desmopressin. 3 Patient began replacement with desmopressin. 2 year later MRI showed persistence of the enlarged pituitary stalk and loss of the posterior pituitary. 3 years after presentation, MRI showed reduction of the enlarged stalk, and still loss of the posterior hyperintense signal. Patient still required desmopressin.
258 Hormone replacement None or not specified Just desmopressin Patient began desmopressin replacement. 6 months later MRI showed disappearance of the thickening of the pituitary stalk, but a persistent lack of the posterior high signal. Desmopressin had been discontinued and endocrine test showed incomplete recovery of ADH secretion. 10 months later the patient was well without headache, fever, polydipsia or polyuria. 0 Patient began desmopressin replacement. 6 months later MRI showed disappearance of the thickening of the pituitary stalk, but a persistent lack of the posterior high signal. Desmopressin had been discontinued and endocrine test showed incomplete recovery of ADH secretion. 10 months later the patient was well without headache, fever, polydipsia or polyuria.
101 Hormone replacement None or not specified Glucocorticoids 4 months later, under thyroxine, hydrocortisone and desmopressin, she showed recovery of pituitary function. Hydrocortisone was tapered and then discontinued. MRI performed 1.5 years later showed a pituitary of normal size. Only a small intrasellar arachnoid cyst without any other abnormalities. 1 4 months later, under thyroxine, hydrocortisone and desmopressin, she showed recovery of pituitary function. Hydrocortisone was tapered and then discontinued. MRI performed 1.5 years later showed a pituitary of normal size. Only a small intrasellar arachnoid cyst without any other abnormalities.
209 Hormone replacement None or not specified More than two hormones Replacement therapy with desmopressin and GH Replacement therapy with desmopressin and GH
305 Hormone replacement None or not specified More than two hormones The patient began desmopressin for diabetes insipidus and chorionic gonadotropin from the hypogonadism. MRIs perfumed 0.5, 1 and 1.5 years later still showed nodular enlargement and thickening of the pituitary stalk. 1 The patient began desmopressin for diabetes insipidus and chorionic gonadotropin from the hypogonadism. MRIs perfumed 0.5, 1 and 1.5 years later still showed nodular enlargement and thickening of the pituitary stalk.
219 Hormone replacement None or not specified Glucocorticoids
208 Hormone replacement None or not specified More than two hormones Replacement therapy with desmopressin, thyroxine and GH Replacement therapy with desmopressin, thyroxine and GH
204 Hormone replacement None or not specified Glucocorticoids The patient was on hydrocortisone replacement therapy. She had a transient thyrotoxicosis. MRI at 5 months after the initial examination showed a significant decrease in height of the mass. 4 years later the patient is well on hydrocortisone replacement. 4 The patient was on hydrocortisone replacement therapy. She had a transient thyrotoxicosis. MRI at 5 months after the initial examination showed a significant decrease in height of the mass. 4 years later the patient is well on hydrocortisone replacement.
141 Hormone replacement None or not specified Glucocorticoids Patient required hydrocortisone replacement and treatment for her Graves' disease. Patient required hydrocortisone replacement and treatment for her Graves' disease.
343 Hormone replacement None or not specified Glucocorticoids Patient began anti-thyroid drug therapy with symptom improvement Patient began anti-thyroid drug therapy with symptom improvement
117 Hormone replacement None or not specified Glucocorticoids 8.5 months after delivery thyroid function was normal, PRL decreased, gonadotropins normalized, GH responded to the hypoglycemia. There was still a residual adrenal insufficiency. The patient required cortisone acetate replacement. 18 months post-partum, although menses had not returned, she was well. 1 8.5 months after delivery thyroid function was normal, PRL decreased, gonadotropins normalized, GH responded to the hypoglycemia. There was still a residual adrenal insufficiency. The patient required cortisone acetate replacement. 18 months post-partum, although menses had not returned, she was well.
118 Hormone replacement None or not specified Glucocorticoids Patient required replacement therapy with hydrocortisone 0 Patient required replacement therapy with hydrocortisone
29 Hormone replacement None or not specified Glucocorticoids Symptoms improved with steroid replacement therapy, with appearance of regular and ovulatory cycles. Symptoms improved with steroid replacement therapy, with appearance of regular and ovulatory cycles.
263 Hormone replacement None or not specified Just desmopressin Patient began desmopressin with resolution of the symptoms. Two months later, MRI was unchanged in comparison to the one performed before the treatment. 0 Patient began desmopressin with resolution of the symptoms. Two months later, MRI was unchanged in comparison to the one performed before the treatment.
121 Hormone replacement None or not specified More than two hormones 8 months after delivery (3 months after presentation) MRI was normal. 12 months after delivery the patient was still amenorrhoic and developed subclinical primary hypothyroidism with TPO antibodies. She was started on thyroxine. 2 years later menses normalized and she was well with thyroxine and desmopressin. MRI showed a normal infundibulum and a partially empty sella. 5 years after delivery she was well with desmopressin and thyroxine. 5 8 months after delivery (3 months after presentation) MRI was normal. 12 months after delivery the patient was still amenorrhoic and developed subclinical primary hypothyroidism with TPO antibodies. She was started on thyroxine. 2 years later menses normalized and she was well with thyroxine and desmopressin. MRI showed a normal infundibulum and a partially empty sella. 5 years after delivery she was well with desmopressin and thyroxine.
273 Hormone replacement None or not specified Just desmopressin Patient began replacement with desmopressin (30 mcg per day). 6 months later the patient still required desmopressin but the dosage was reduced to 15 mcg per day. 0 Patient began replacement with desmopressin (30 mcg per day). 6 months later the patient still required desmopressin but the dosage was reduced to 15 mcg per day.
24 Hormone replacement None or not specified Glucocorticoids On admission patient began thyroxine and hydrocortisone replacement with clear clinical improvement. She had her first normal menstrual period after 2 months of therapy (7 month post-partum). 18 months after delivery she conceived. This second pregnancy was also uneventful under thyroxine. Delivery was normal but again she was unable to lactate 4 On admission patient began thyroxine and hydrocortisone replacement with clear clinical improvement. She had her first normal menstrual period after 2 months of therapy (7 month post-partum). 18 months after delivery she conceived. This second pregnancy was also uneventful under thyroxine. Delivery was normal but again she was unable to lactate
177 Hormone replacement None or not specified Just desmopressin Patient began desmopressin replacement. MRI performed 1 year and 4 years after admission, showed progressive disappearance of the findings. In the 4 year later MRI, there was still loss of the posterior hyperintense signal. Endocrine tests showed reduction of the ACTH, GH, and hyperesponsive prolactin 4 Patient began desmopressin replacement. MRI performed 1 year and 4 years after admission, showed progressive disappearance of the findings. In the 4 year later MRI, there was still loss of the posterior hyperintense signal. Endocrine tests showed reduction of the ACTH, GH, and hyperesponsive prolactin
100 Hormone replacement None or not specified Glucocorticoids Patient responded well to thyroxine and hydrocortisone replacement. Patient responded well to thyroxine and hydrocortisone replacement.
303 Hormone replacement None or not specified Just desmopressin Patient began desmopressin with marked improvement of his symptoms. MRIs performed 1, 2 an 3 years later showed persistence of the abnormal nodular enlargement of the posterior lobe, and thickening of the pituitary stalk. The anterior lobe was normal in size, shape and enhancement. Diabetes insipidus continued but was well controlled with desmopressin acetate. 3 Patient began desmopressin with marked improvement of his symptoms. MRIs performed 1, 2 an 3 years later showed persistence of the abnormal nodular enlargement of the posterior lobe, and thickening of the pituitary stalk. The anterior lobe was normal in size, shape and enhancement. Diabetes insipidus continued but was well controlled with desmopressin acetate.
255 Hormone replacement None or not specified Just desmopressin Patient was treated with desmopressin. 2 months following the diagnosis she is well, but she cannot be weaned from desmopressin, indicating that the lesion causing diabetes insipidus persists. She has stop breast-feeding and has minimal lactation. Her prolactin has returned to normal but the patient remains amenorrhoic. Thyroid function tests and GH production are unchanged. 0 Patient was treated with desmopressin. 2 months following the diagnosis she is well, but she cannot be weaned from desmopressin, indicating that the lesion causing diabetes insipidus persists. She has stop breast-feeding and has minimal lactation. Her prolactin has returned to normal but the patient remains amenorrhoic. Thyroid function tests and GH production are unchanged.
241 Hormone replacement None or not specified Glucocorticoids Patient received high methylprednisolone iv pulses. 19 months after diagnosis: diabetes insipidus ceased. The ACTH impairment persisted. MRI showed no change of the sellar content. 1 Patient received high methylprednisolone iv pulses. 19 months after diagnosis: diabetes insipidus ceased. The ACTH impairment persisted. MRI showed no change of the sellar content.
358 Hormone replacement None or not specified Just desmopressin Patient began desmopressin and was discharged 30 days after admission. 1.5 years later he still required desmopressin and MRI was unchanged. 1 Patient began desmopressin and was discharged 30 days after admission. 1.5 years later he still required desmopressin and MRI was unchanged.
357 Hormone replacement None or not specified Just desmopressin Patient started desmopressin. He was discharged 23 days after admission; endocrine tests for anterior hypophysis were normal. 5 years later MRI is still abnormal and patient still requires desmopressin. 5 Patient started desmopressin. He was discharged 23 days after admission; endocrine tests for anterior hypophysis were normal. 5 years later MRI is still abnormal and patient still requires desmopressin.
71 Hormone replacement None or not specified Glucocorticoids After delivery she was able to lactate and the mass decreased in size. 5 months post-partum GH and cortisol was reduced and not responsive. She required steroids replacement. 0 After delivery she was able to lactate and the mass decreased in size. 5 months post-partum GH and cortisol was reduced and not responsive. She required steroids replacement.
174 Hormone replacement None or not specified Glucocorticoids Patient did well with hydrocortisone. 6 years after delivery, MRI showed a further reduction of the pituitary mass to 2.5 mm. The pituitary was so atrophic that the optic chiasm dropped to the sella turcica. Empty sella. 6 Patient did well with hydrocortisone. 6 years after delivery, MRI showed a further reduction of the pituitary mass to 2.5 mm. The pituitary was so atrophic that the optic chiasm dropped to the sella turcica. Empty sella.
304 Hormone replacement None or not specified Just desmopressin Patient began desmopressin with correction of her symptomatology. One year later MRI still showed nodular enlargement and thickening of the pituitary stalk. She continued desmopressin replacement. 1 Patient began desmopressin with correction of her symptomatology. One year later MRI still showed nodular enlargement and thickening of the pituitary stalk. She continued desmopressin replacement.
23 None None or not specified None or not specified One month after a normal delivery symptoms improved spontaneously, although the patient was unable to lactate. 1 year after delivery CT showed disappearance of the pituitary mass. GH, PRL, ACTH and cortisol were slightly reduced. 1 One month after a normal delivery symptoms improved spontaneously, although the patient was unable to lactate. 1 year after delivery CT showed disappearance of the pituitary mass. GH, PRL, ACTH and cortisol were slightly reduced.
47 Hormone replacement None or not specified More than two hormones The patient was scheduled for surgery for a diagnosis of lymphocytic hypophysitis, and started on steroids. However, 2 months after delivery visual filed normalized and CT scan showed a reduction in size of the pituitary. About 6 months after delivery she developed nausea, fatigue, weight loss and axillary muscle pain. Endocrine tests showed suppressed response of ACTH, GH and PRL to the stimulus. 1 year after delivery CT scan was normal and endocrine tests unchanged 1 The patient was scheduled for surgery for a diagnosis of lymphocytic hypophysitis, and started on steroids. However, 2 months after delivery visual filed normalized and CT scan showed a reduction in size of the pituitary. About 6 months after delivery she developed nausea, fatigue, weight loss and axillary muscle pain. Endocrine tests showed suppressed response of ACTH, GH and PRL to the stimulus. 1 year after delivery CT scan was normal and endocrine tests unchanged
342 Hormone replacement None or not specified More than two hormones Patient began replacement with hydrocortisone, thyroxine and hGH. 2 Patient began replacement with hydrocortisone, thyroxine and hGH.
306 Hormone replacement None or not specified More than two hormones Patient began treatment with hydrocortisone with improvement of symptoms. She was then moved to the regular ward of the hospital. After this therapy she developed central diabetes insipidus (7 liters/day), which was corrected with desmopressin. She then began thyroxine to correct the hypothyroidism 0 Patient began treatment with hydrocortisone with improvement of symptoms. She was then moved to the regular ward of the hospital. After this therapy she developed central diabetes insipidus (7 liters/day), which was corrected with desmopressin. She then began thyroxine to correct the hypothyroidism
95 Hormone replacement None or not specified More than two hormones
33 None None or not specified None or not specified Repeated CT scan, 1 year from the previous one, showed disappearance of the pituitary mass 1 Repeated CT scan, 1 year from the previous one, showed disappearance of the pituitary mass
34 None None or not specified None or not specified Repeated CT scan, 1 month from the previous one, showed disappearance of the pituitary mass. Symptoms gradually disappeared with anti-inflammatory Repeated CT scan, 1 month from the previous one, showed disappearance of the pituitary mass. Symptoms gradually disappeared with anti-inflammatory
35 None None or not specified None or not specified Repeated CT scan, 7 months from the previous one, showed disappearance of the pituitary mass. Symptoms gradually disappeared with anti-inflammatory 0 Repeated CT scan, 7 months from the previous one, showed disappearance of the pituitary mass. Symptoms gradually disappeared with anti-inflammatory
42 None None or not specified None or not specified Visual fields normalized 3 months after delivery. Also the pituitary mass was no longer visible in CT scans. 0 Visual fields normalized 3 months after delivery. Also the pituitary mass was no longer visible in CT scans.
63 None None or not specified None or not specified visual fields spontaneously improved. She delivered in the 9th month by cesarean section. Visual fields improved and MRI showed a reduction in the pituitary height. 1 year after delivery MRI (5 mm height) and all endocrine tests were normal. She became pregnant a second time. MRI showed normal pituitary height. 1 visual fields spontaneously improved. She delivered in the 9th month by cesarean section. Visual fields improved and MRI showed a reduction in the pituitary height. 1 year after delivery MRI (5 mm height) and all endocrine tests were normal. She became pregnant a second time. MRI showed normal pituitary height.
86 None None or not specified None or not specified At about 1 year after delivery, normal adrenal and thyroid function. Only TPO antibodies remained positive. 1 At about 1 year after delivery, normal adrenal and thyroid function. Only TPO antibodies remained positive.
97 None None or not specified None or not specified Pituitary function restored 1.5 years later, along with the disappearance of the pituitary mass 1 Pituitary function restored 1.5 years later, along with the disappearance of the pituitary mass
283 Hormone replacement None or not specified Glucocorticoids The patient began hydrocortisone with improvement of her symptoms. MRI performed 6 months later showed a reduction of the pituitary size. MRI performed 12 months later was unchanged. 1 The patient began hydrocortisone with improvement of her symptoms. MRI performed 6 months later showed a reduction of the pituitary size. MRI performed 12 months later was unchanged.
194 None None or not specified None or not specified Headaches disappeared 2 months later when MRI showed a gland height of 8 mm. Gonadotropins were still impaired and now also prolactin did not response to the stimulus. 1 year later the patient was asymptomatic, endocrine tests were the same as the previous ones and MRI showed a normal anterior pituitary by a thickened (4 mm) pituitary stalk. 1.5 years later endocrine tests were all normal and MRI was unchanged. 3.5 years later endocrine tests and MRI were all normal. 3 Headaches disappeared 2 months later when MRI showed a gland height of 8 mm. Gonadotropins were still impaired and now also prolactin did not response to the stimulus. 1 year later the patient was asymptomatic, endocrine tests were the same as the previous ones and MRI showed a normal anterior pituitary by a thickened (4 mm) pituitary stalk. 1.5 years later endocrine tests were all normal and MRI was unchanged. 3.5 years later endocrine tests and MRI were all normal.
163 Hormone replacement None or not specified Glucocorticoids Patient is doing well under hydrocortisone treatment. MRI performed 3 years later revealed no changes in the pituitary. An MRI performed 6 years later showed an empty sella. 6 Patient is doing well under hydrocortisone treatment. MRI performed 3 years later revealed no changes in the pituitary. An MRI performed 6 years later showed an empty sella.
122 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient began prednisone and thyroxine with complete resolution of symptoms, including resumption of menses. A repeat MRI 11 months later was normal with no change from the previous one. 1 Patient began prednisone and thyroxine with complete resolution of symptoms, including resumption of menses. A repeat MRI 11 months later was normal with no change from the previous one.
159 Hormone replacement None or not specified More than two hormones Patient began replacement with desmopressin. 3 years later MRI showed decreased, but still enlarged pituitary stalk, still persistence of the loss of the posterior pituitary and decreased anterior pituitary. Endocrine tests were still abnormal 3 Patient began replacement with desmopressin. 3 years later MRI showed decreased, but still enlarged pituitary stalk, still persistence of the loss of the posterior pituitary and decreased anterior pituitary. Endocrine tests were still abnormal
238 Hormone replacement None or not specified More than two hormones Patient received high methylprednisolone iv pulses. 42 months after diagnosis the diabetes insipidus ceased. There was still an impairment of GH. MRI showed shrinkage of the sellar content; the pituitary stalk was still somewhat enlarged. 3 Patient received high methylprednisolone iv pulses. 42 months after diagnosis the diabetes insipidus ceased. There was still an impairment of GH. MRI showed shrinkage of the sellar content; the pituitary stalk was still somewhat enlarged.
239 Hormone replacement None or not specified More than two hormones Patient received high methylprednisolone iv pulses. 3 years after diagnosis: normalization of gonadotropins; improvement of TSH. ACTH and PRL still impaired. MRI showed shrinkage of sellar content. 3 Patient received high methylprednisolone iv pulses. 3 years after diagnosis: normalization of gonadotropins; improvement of TSH. ACTH and PRL still impaired. MRI showed shrinkage of sellar content.
240 Hormone replacement None or not specified More than two hormones Patient received high methylprednisolone iv pulses. 27 months after diagnosis: normalization of ACTH; improvement of GH and diabetes insipidus. MRI showed shrinkage of the thickened pituitary stalk. 2 Patient received high methylprednisolone iv pulses. 27 months after diagnosis: normalization of ACTH; improvement of GH and diabetes insipidus. MRI showed shrinkage of the thickened pituitary stalk.
266 Hormone replacement None or not specified More than two hormones Because of the authors' experience with case 1, it was decided not to operate. The child became hypothyroid and required thyroxine replacement. Development and neurological function were normal. MRI from age 5 through age 8 demonstrated a fading residual enhancing abnormality. 4 Because of the authors' experience with case 1, it was decided not to operate. The child became hypothyroid and required thyroxine replacement. Development and neurological function were normal. MRI from age 5 through age 8 demonstrated a fading residual enhancing abnormality.
158 Hormone replacement None or not specified More than two hormones
32 Hormone replacement None or not specified Glucocorticoids The patient received replacement therapy with thyroxine and hydrocortisone. 3 months after delivery, thyroxine was discontinued. CT scan showed disappearance of the pituitary mass. 1 year after delivery CT scan showed a normal sella. Patient was on hydrocortisone acetate. 1 The patient received replacement therapy with thyroxine and hydrocortisone. 3 months after delivery, thyroxine was discontinued. CT scan showed disappearance of the pituitary mass. 1 year after delivery CT scan showed a normal sella. Patient was on hydrocortisone acetate.
28 Hormone replacement None or not specified Glucocorticoids Symptoms improved with steroid replacement therapy, with appearance of regular and ovulatory cycles. Symptoms improved with steroid replacement therapy, with appearance of regular and ovulatory cycles.
207 Hormone replacement None or not specified More than two hormones Replacement therapy with desmopressin, thyroxine and glucocorticoid Replacement therapy with desmopressin, thyroxine and glucocorticoid
40 Hormone replacement None or not specified Glucocorticoids Patient began hydrocortisone replacement with weight gain and improvement of fatigue and cold intolerance. 6 months later she was feeling well but still amenorrhoic. 1 Patient began hydrocortisone replacement with weight gain and improvement of fatigue and cold intolerance. 6 months later she was feeling well but still amenorrhoic.
172 None None or not specified None or not specified Menses returned 5 months post-partum and she conceived for the 4th time at 8 months post-partum. Again headaches and vomiting, this time in the 2nd trimester. Post-partum was fine. She was sterilized. Repeated CT scan showed no tumor and normal pituitary size. Patient is asymptomatic. 0 Menses returned 5 months post-partum and she conceived for the 4th time at 8 months post-partum. Again headaches and vomiting, this time in the 2nd trimester. Post-partum was fine. She was sterilized. Repeated CT scan showed no tumor and normal pituitary size. Patient is asymptomatic.
376 Hormone replacement None or not specified Thyroxine Patient was started on thyroxine replacement. 1 Patient was started on thyroxine replacement.
272 Hormone replacement None or not specified Just desmopressin A biopsy of the right submandibular gland showed massive infiltration of T and B lymphocytes, with some plasma cells and fibrosis. Patient began replacement with desmopressin. 1.5 years later he still required desmopressin, although at a reduced dosage. 1 A biopsy of the right submandibular gland showed massive infiltration of T and B lymphocytes, with some plasma cells and fibrosis. Patient began replacement with desmopressin. 1.5 years later he still required desmopressin, although at a reduced dosage.
162 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient received replacement therapy with thyroxine and hydrocortisone. Estrogen returned to normal levels. At 6 months post-partum CT scan shoed complete resolution of the pituitary mass. The patient became then pregnant on 3 occasions: the first 2 ended in spontaneous abortion; the 3rd one was brought successfully to term. No problem during the 2nd pregnancy or in the second post-partum period. No adjustment of the replacement therapy required. 2 Patient received replacement therapy with thyroxine and hydrocortisone. Estrogen returned to normal levels. At 6 months post-partum CT scan shoed complete resolution of the pituitary mass. The patient became then pregnant on 3 occasions: the first 2 ended in spontaneous abortion; the 3rd one was brought successfully to term. No problem during the 2nd pregnancy or in the second post-partum period. No adjustment of the replacement therapy required.
220 Hormone replacement None or not specified Just desmopressin Patient began replacement with desmopressin. 5 years later, MRI showed disappearance of the pituitary mass. 5 Patient began replacement with desmopressin. 5 years later, MRI showed disappearance of the pituitary mass.
251 None None or not specified None or not specified Symptoms improved spontaneously, without therapy. 3 months after onset, CT scan showed that the pituitary mass had returned to the normal size of the pituitary gland. 1 year after onset, CT scan showed that the pituitary gland had become smaller with an empty sella appearance. 8 years later no recurrence was detected and the patient has not needed hormone replacement therapy. 8 Symptoms improved spontaneously, without therapy. 3 months after onset, CT scan showed that the pituitary mass had returned to the normal size of the pituitary gland. 1 year after onset, CT scan showed that the pituitary gland had become smaller with an empty sella appearance. 8 years later no recurrence was detected and the patient has not needed hormone replacement therapy.
293 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient required replacement with thyroxine and hydrocortisone. Patient required replacement with thyroxine and hydrocortisone.
231 Hormone replacement None or not specified Just desmopressin After 5 days symptoms (fever) improved and diabetes insipidus was corrected by desmopressin administration. 2 months after admission, endocrine tests showed persistence of low GH, increased prolactin. 6 months after admission, MRI showed reduction of the stalk thickening and persistence of the hyperintense signal loss. 0 After 5 days symptoms (fever) improved and diabetes insipidus was corrected by desmopressin administration. 2 months after admission, endocrine tests showed persistence of low GH, increased prolactin. 6 months after admission, MRI showed reduction of the stalk thickening and persistence of the hyperintense signal loss.
173 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) She was started on prednisolone and thyroxine replacement therapy, with marked improvement. MRI done two years later showed no sellar mass. 2 She was started on prednisolone and thyroxine replacement therapy, with marked improvement. MRI done two years later showed no sellar mass.
55 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) 4 months later CT scan showed reduction of the mass and a normal appearing pituitary. Patient required replacement therapy with thyroxine and cortisone acetate. 5 years later CT scan showed an empty sella. 10 years later the patient became pregnant and delivered a healthy infant at term. Postpartum was uneventful. 10 4 months later CT scan showed reduction of the mass and a normal appearing pituitary. Patient required replacement therapy with thyroxine and cortisone acetate. 5 years later CT scan showed an empty sella. 10 years later the patient became pregnant and delivered a healthy infant at term. Postpartum was uneventful.
198 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient was treated with steroids and thyroxine that resolved the headache, fever and inflammation. She was discharged. Two months later menses returned. MRI showed gradual reduction of the pituitary mass: the last MRI, 9.5 months after treatment initiation, showed disappearance of the pituitary mass. At 16 months after therapy, TSH reaction and GH-RH normalized, but there was still unresponsiveness of ACTH to CRH and poor response of gonadotropins to GnRH 1 Patient was treated with steroids and thyroxine that resolved the headache, fever and inflammation. She was discharged. Two months later menses returned. MRI showed gradual reduction of the pituitary mass: the last MRI, 9.5 months after treatment initiation, showed disappearance of the pituitary mass. At 16 months after therapy, TSH reaction and GH-RH normalized, but there was still unresponsiveness of ACTH to CRH and poor response of gonadotropins to GnRH
294 Hormone replacement None or not specified Thyroxine Patient began replacement with thyroxine. 10 months after diagnosis he was well with this medications. 0 Patient began replacement with thyroxine. 10 months after diagnosis he was well with this medications.
290 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient began replacement with thyroxine and hydrocortisone, with rapid improvement of symptoms. MRI performed 3 months later showed a rather small, but otherwise normal appearing, pituitary, with only minimal enhancement of the sellar diaphragm. 1.5 years after the initial presentation, the patient is well with her hormonal replacement therapy. 1 Patient began replacement with thyroxine and hydrocortisone, with rapid improvement of symptoms. MRI performed 3 months later showed a rather small, but otherwise normal appearing, pituitary, with only minimal enhancement of the sellar diaphragm. 1.5 years after the initial presentation, the patient is well with her hormonal replacement therapy.
339 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) 3 weeks after delivery, at the time when the endocrine tests were done, she began replacement with thyroxine and hydrocortisone. Headaches completely resolved in 3 days. 4 months postpartum MRI showed complete resolution of the pituitary mass. At 12 months, thyroxine was withdrawn and her thyroid function remained normal. At 24 months she is well under steroid replacement. 2 3 weeks after delivery, at the time when the endocrine tests were done, she began replacement with thyroxine and hydrocortisone. Headaches completely resolved in 3 days. 4 months postpartum MRI showed complete resolution of the pituitary mass. At 12 months, thyroxine was withdrawn and her thyroid function remained normal. At 24 months she is well under steroid replacement.
292 Hormone replacement None or not specified Growth hormone The patient started again bromocriptine, which was then switched to cabergoline, but both were stopped because of side effects. She also stopped the oral contraceptive. 5 months later galactorrhea disappeared and menses returned. Endocrine studies showed persistence of the secondary hypothyroidism, an undetectable GH and a prolactin also undetectable. MRI findings were unchanged. 9 months after presentation MRI showed a reduction in pituitary lesion and 18 months after presentation a normal pituitary. Patient began replacement with recombinant GH and wishes a second child. 1 The patient started again bromocriptine, which was then switched to cabergoline, but both were stopped because of side effects. She also stopped the oral contraceptive. 5 months later galactorrhea disappeared and menses returned. Endocrine studies showed persistence of the secondary hypothyroidism, an undetectable GH and a prolactin also undetectable. MRI findings were unchanged. 9 months after presentation MRI showed a reduction in pituitary lesion and 18 months after presentation a normal pituitary. Patient began replacement with recombinant GH and wishes a second child.
243 Hormone replacement None or not specified Growth hormone Patient received high methylprednisolone iv pulses. 19 months after diagnosis: persistent GH impairment. MRI showed shrinkage of the sellar content and the pituitary stalk. 1 Patient received high methylprednisolone iv pulses. 19 months after diagnosis: persistent GH impairment. MRI showed shrinkage of the sellar content and the pituitary stalk.
171 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) 1.5 years after the fist CT scan, the repeated CT scan showed no mass and a pituitary of normal size. Patient continues to be on prednisolone and thyroxine replacement and is asymptotic. 1 1.5 years after the fist CT scan, the repeated CT scan showed no mass and a pituitary of normal size. Patient continues to be on prednisolone and thyroxine replacement and is asymptotic.
282 Hormone replacement None or not specified Just desmopressin 3 months later she developed loss of visual acuity, mydriasis and central visual defect in the right eye. MRI showed hyperintense signal from the whole right optic nerve, diagnosed as optic neuritis. Patient received steroid. 27 months later there are no ophthalmologic symptoms and she is well with desmopressin replacement 2 3 months later she developed loss of visual acuity, mydriasis and central visual defect in the right eye. MRI showed hyperintense signal from the whole right optic nerve, diagnosed as optic neuritis. Patient received steroid. 27 months later there are no ophthalmologic symptoms and she is well with desmopressin replacement
169 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient was started on thyroxine and hydrocortisone replacement therapy with clinical improvement and reduction of the pituitary mass by MRI. 6 months later she still required hormone replacement. 0 Patient was started on thyroxine and hydrocortisone replacement therapy with clinical improvement and reduction of the pituitary mass by MRI. 6 months later she still required hormone replacement.
289 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) She began thyroxine and hydrocortisone replacement, and was given dexamethasone (4 mg/4 times a day) for a presumed diagnosis of lymphocytic hypophysitis. Symptoms improved. An MRI performed 4 days later showed a considerable reduction of the mass, not compressing anymore the optic chiasm. 0 She began thyroxine and hydrocortisone replacement, and was given dexamethasone (4 mg/4 times a day) for a presumed diagnosis of lymphocytic hypophysitis. Symptoms improved. An MRI performed 4 days later showed a considerable reduction of the mass, not compressing anymore the optic chiasm.
193 Hormone replacement None or not specified Just desmopressin
20 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient was started on cortisone acetate and propranolol with improvement of her symptoms and normalization of the calcemia. 2 months later she developed hypothyroidism and thyroxine replacement was begun. 4.5 months later CT scan showed a pituitary of nearly normal size. Menses had not returned; she was well with the replacement therapy 0 Patient was started on cortisone acetate and propranolol with improvement of her symptoms and normalization of the calcemia. 2 months later she developed hypothyroidism and thyroxine replacement was begun. 4.5 months later CT scan showed a pituitary of nearly normal size. Menses had not returned; she was well with the replacement therapy
81 Hormone replacement None or not specified Glucocorticoids Symptoms improved spontaneously after delivery and at 2 weeks MRI showed that the height of the mass was 13.4. She however felt tired and anorectic and was admitted, 3 months after delivery, to the hospital. A postpartum thyroiditis was diagnosed: high T4, suppressed TSH , almost no technetium uptake, associated with adrenal insufficiency. Hydrocortisone was administered with improvements of her symptoms and reduction of the pituitary mass (4.9 mm on MRI 2 months after delivery) 0 Symptoms improved spontaneously after delivery and at 2 weeks MRI showed that the height of the mass was 13.4. She however felt tired and anorectic and was admitted, 3 months after delivery, to the hospital. A postpartum thyroiditis was diagnosed: high T4, suppressed TSH , almost no technetium uptake, associated with adrenal insufficiency. Hydrocortisone was administered with improvements of her symptoms and reduction of the pituitary mass (4.9 mm on MRI 2 months after delivery)
268 Hormone replacement None or not specified Thyroxine The confusional status and the hepatic function improved after starting L-thyroxine therapy. The confusional status and the hepatic function improved after starting L-thyroxine therapy.
176 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) 18 months after diagnosis MRI showed a reduction of the pituitary and stalk volume. 24 months after diagnosis MRI showed empty sella and atrophy of the pituitary stalk 2 18 months after diagnosis MRI showed a reduction of the pituitary and stalk volume. 24 months after diagnosis MRI showed empty sella and atrophy of the pituitary stalk
242 Hormone replacement None or not specified Glucocorticoids Patient received high methylprednisolone iv pulses. 19 months after diagnosis: diabetes insipidus ceased; gonadotropins normalized; GH improved. The ACTH impairment persisted. MRI showed shrinkage of the pituitary stalk. 1 Patient received high methylprednisolone iv pulses. 19 months after diagnosis: diabetes insipidus ceased; gonadotropins normalized; GH improved. The ACTH impairment persisted. MRI showed shrinkage of the pituitary stalk.
234 Hormone replacement None or not specified Just desmopressin Patient began replacement with desmopressin. 9 months later, MRI showed normalization of the infundibular thickening, with persistence loss of the hyperintense signal of the neurohypophysis. 20 months later no clinical changes were observed. 1 Patient began replacement with desmopressin. 9 months later, MRI showed normalization of the infundibular thickening, with persistence loss of the hyperintense signal of the neurohypophysis. 20 months later no clinical changes were observed.
218 Hormone replacement None or not specified Glucocorticoids Patient required hydrocortisone replacement, which resulted in marked clinical improvement Patient required hydrocortisone replacement, which resulted in marked clinical improvement
221 Hormone replacement None or not specified Just desmopressin Patient began replacement with desmopressin. 2.5 years later, MRI showed disappearance of the swelling of the pituitary stalk and pituitary mass. 2 Patient began replacement with desmopressin. 2.5 years later, MRI showed disappearance of the swelling of the pituitary stalk and pituitary mass.
138 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient required replacement therapy with thyroxine and hydrocortisone. Repeated MRI performed 10 months post-partum showed normalization of the pituitary size. 0 Patient required replacement therapy with thyroxine and hydrocortisone. Repeated MRI performed 10 months post-partum showed normalization of the pituitary size.
340 Hormone replacement None or not specified Glucocorticoids Patient began steroid replacement therapy with marked improvement of the symptoms Patient began steroid replacement therapy with marked improvement of the symptoms
223 Hormone replacement None or not specified Just desmopressin Patient began replacement with desmopressin. 10 months after diagnosis she developed secondary hypocortisolism and began steroid replacement. 12 months after diagnosis MRI showed reduction of the pituitary mass 1 Patient began replacement with desmopressin. 10 months after diagnosis she developed secondary hypocortisolism and began steroid replacement. 12 months after diagnosis MRI showed reduction of the pituitary mass
140 Hormone replacement None or not specified Glucocorticoids Patient required replacement therapy with hydrocortisone. Thyroxine could be withdrawn 3 years after delivery. Repeated CT scan 4 months post-partum showed a 90% reduction in pituitary size, and an MRI 2 years after presentation was normal. 2 Patient required replacement therapy with hydrocortisone. Thyroxine could be withdrawn 3 years after delivery. Repeated CT scan 4 months post-partum showed a 90% reduction in pituitary size, and an MRI 2 years after presentation was normal.
137 Hormone replacement None or not specified Thyroxine Patient began replacement therapy with thyroxine and hydrocortisone. Menses resumed 1 month later and she got pregnant a second time 4 months later, delivering then at term and without complications. It was possible to withdraw thyroxine replacement, but not hydrocortisone. 0 Patient began replacement therapy with thyroxine and hydrocortisone. Menses resumed 1 month later and she got pregnant a second time 4 months later, delivering then at term and without complications. It was possible to withdraw thyroxine replacement, but not hydrocortisone.
139 Hormone replacement None or not specified Thyroxine Patient required replacement therapy with thyroxine. Repeated MRI at 7 months post-partum showed an 80% reduction in the size of the pituitary, and by 12 months post-partum the pituitary size had returned to normal. 1 Patient required replacement therapy with thyroxine. Repeated MRI at 7 months post-partum showed an 80% reduction in the size of the pituitary, and by 12 months post-partum the pituitary size had returned to normal.
191 Hormone replacement None or not specified Glucocorticoids and thyroixine (or other two hormone combination) Patient began replacement therapy with prednisone and then thyroxine. Symptoms improved and menses returned. 9 months later MRI showed significant shrinkage of the sellar mass. 0 Patient began replacement therapy with prednisone and then thyroxine. Symptoms improved and menses returned. 9 months later MRI showed significant shrinkage of the sellar mass.
222 Hormone replacement None or not specified Just desmopressin Patient began replacement with desmopressin. 2 years later, MRI showed reduction of the mass size. 2 Patient began replacement with desmopressin. 2 years later, MRI showed reduction of the mass size.
295 Mass reduction Lympholytic drugs (steroids, azathioprine, methotrexate) None or not specified Patient began prednisone (30 mg/day) for 2 days. Visual acuity improved, but, after 1 month, worsened again. So steroids were started again (iv pulses of solumedol, 1 g/day for 3 days). Sight normalized. 0 Patient began prednisone (30 mg/day) for 2 days. Visual acuity improved, but, after 1 month, worsened again. So steroids were started again (iv pulses of solumedol, 1 g/day for 3 days). Sight normalized.
375 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) Glucocorticoids and thyroixine (or other two hormone combination) Patient was started on prednisone (5 mg AM and 2.5 mg PM). Headache disappeared. Endocrine status did not change and the patient was maintained on prednisone (7.5 mg/day) and thyroxine. 2 Patient was started on prednisone (5 mg AM and 2.5 mg PM). Headache disappeared. Endocrine status did not change and the patient was maintained on prednisone (7.5 mg/day) and thyroxine.
359 Hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) Just desmopressin Patient began steroids. The lesion was also irradiated with total dose of 40 Gy because initially suspected to be a malignant lymphoma. Adenohypophyseal function remained normal. Diabetes insipidus gradually improved. 67 months after treatment the patient is well. MRI showed nearly normal pituitary size. The absence of recurrence, and the good response to short-term steroid administration and 40Gy make the initial suspicion of lymphoma unlikely. 5 Patient began steroids. The lesion was also irradiated with total dose of 40 Gy because initially suspected to be a malignant lymphoma. Adenohypophyseal function remained normal. Diabetes insipidus gradually improved. 67 months after treatment the patient is well. MRI showed nearly normal pituitary size. The absence of recurrence, and the good response to short-term steroid administration and 40Gy make the initial suspicion of lymphoma unlikely.
252 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) More than two hormones
257 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) Glucocorticoids She began steroids with resolution of her symptoms within 10 days. She carried pregnancy to term and delivered vaginally a healthy infant. She was able to lactate and menstruation resumed 2 months postpartum. 6 months post-partum thyroid hormones and prolactin were normal 6 months post-partum, and MRI showed complete resolution of the pituitary mass. 0 She began steroids with resolution of her symptoms within 10 days. She carried pregnancy to term and delivered vaginally a healthy infant. She was able to lactate and menstruation resumed 2 months postpartum. 6 months post-partum thyroid hormones and prolactin were normal 6 months post-partum, and MRI showed complete resolution of the pituitary mass.
85 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) Just desmopressin Patient began steroids with resolution of headaches. MRI showed normalization of pituitary size (5 mm height). Patient, however, quickly developed polyuria, and she began replacement with vasopressin. After 6 months she stopped steroids. Headaches, however, returned and MRI showed again enlargement of the pituitary (13 mm). Patient was hospitalized a second time and restarted steroids. Endocrine tests were the same as those during the first hospitalization. 3 months after discharged, MRI showed normal pituitary, but she continued to required steroids and desmopressin. 0 Patient began steroids with resolution of headaches. MRI showed normalization of pituitary size (5 mm height). Patient, however, quickly developed polyuria, and she began replacement with vasopressin. After 6 months she stopped steroids. Headaches, however, returned and MRI showed again enlargement of the pituitary (13 mm). Patient was hospitalized a second time and restarted steroids. Endocrine tests were the same as those during the first hospitalization. 3 months after discharged, MRI showed normal pituitary, but she continued to required steroids and desmopressin.
374 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) More than two hormones Patient was started on hydrocortisone (40 mg AM and 20 mg PM). His energy improved. He was maintained on corticosteroid (hydrocortisone 40 mg), thyroxine and testosterone. 4 Patient was started on hydrocortisone (40 mg AM and 20 mg PM). His energy improved. He was maintained on corticosteroid (hydrocortisone 40 mg), thyroxine and testosterone.
125 Mass reduction Lympholytic drugs (steroids, azathioprine, methotrexate) None or not specified Treated with steroids to reduce the pituitary mass Treated with steroids to reduce the pituitary mass
348 Mass reduction Lympholytic drugs (steroids, azathioprine, methotrexate) None or not specified Patient improved quickly after administration of hydrocortisone, which brought to light the diabetes insipidus. This was corrected with desmopressin. MRI normalized in about 1 month. Cortisol and urine output normalized without hydrocortisone and vasopressin in 6 months. Hypothyroidism also improved but TSH remained elevated. 0 Patient improved quickly after administration of hydrocortisone, which brought to light the diabetes insipidus. This was corrected with desmopressin. MRI normalized in about 1 month. Cortisol and urine output normalized without hydrocortisone and vasopressin in 6 months. Hypothyroidism also improved but TSH remained elevated.
356 Mass reduction Lympholytic drugs (steroids, azathioprine, methotrexate) None or not specified Patient received high dose intravenous methylprednisolone (rather than surgery) to relieve the severe visual impairment. Patient responded well to this treatment. 6 months later endocrine function was normal 0 Patient received high dose intravenous methylprednisolone (rather than surgery) to relieve the severe visual impairment. Patient responded well to this treatment. 6 months later endocrine function was normal
362 Mass reduction Lympholytic drugs (steroids, azathioprine, methotrexate) None or not specified Pituitary biopsy was not performed because the authors considered the diagnosis of lymphocytic hypophysitis highly probable. Patient began high dose steroids (prednisone 80 mg/day). Proptosis normalized after 8 days; after 30 days cranial and orbital MRI were normal. Steroids were tapered to 8 mg. Patient became pregnant a 4th time. Pregnancy and delivery were uneventful. Two years after delivery, thyroid enlarged, TSH was still suppressed, FT4 increased and TSH receptor antibodies increased. Patient began carbimazole. 8 years after presentation, pituitary function and MRI were normal. 8 Pituitary biopsy was not performed because the authors considered the diagnosis of lymphocytic hypophysitis highly probable. Patient began high dose steroids (prednisone 80 mg/day). Proptosis normalized after 8 days; after 30 days cranial and orbital MRI were normal. Steroids were tapered to 8 mg. Patient became pregnant a 4th time. Pregnancy and delivery were uneventful. Two years after delivery, thyroid enlarged, TSH was still suppressed, FT4 increased and TSH receptor antibodies increased. Patient began carbimazole. 8 years after presentation, pituitary function and MRI were normal.
232 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) Glucocorticoids Patient began steroids therapy (60 mg/day). 25 days later MRI showed reduction of the thickened stalk and meningi 0 Patient began steroids therapy (60 mg/day). 25 days later MRI showed reduction of the thickened stalk and meningi
373 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) Estrogen or androgen replacement Patient was suspected of having lymphocytic hypophysitis and started on dexamethasone (1 mg/day) and methotrexate (12.5 mg/wk). The endocrine status did not change. Patient was maintained on desmopressin (testosterone?) 2 Patient was suspected of having lymphocytic hypophysitis and started on dexamethasone (1 mg/day) and methotrexate (12.5 mg/wk). The endocrine status did not change. Patient was maintained on desmopressin (testosterone?)
197 Mass reduction and hormone replacement Lympholytic drugs (steroids, azathioprine, methotrexate) Glucocorticoids Patient began steroid with almost complete disappearance of the mass Patient began steroid with almost complete disappearance of the mass
379 Mass reduction Lympholytic drugs (steroids, azathioprine, methotrexate) More than two hormones Patient had a complete pituitary insufficiency and diabetes insipidus requiring replacement 0.5 years after surgery. 0 Patient had a complete pituitary insufficiency and diabetes insipidus requiring replacement 0.5 years after surgery.
344 Mass reduction Lympholytic drugs (steroids, azathioprine, methotrexate) None or not specified Patient began prednisolone for the treatment of SLE, and continued desmopressin and the im injections of hCG. 1 month later, MRI showed a marked reduction of the thickening of the pituitary stalk and posterior pituitary. 0 Patient began prednisolone for the treatment of SLE, and continued desmopressin and the im injections of hCG. 1 month later, MRI showed a marked reduction of the thickening of the pituitary stalk and posterior pituitary.
11 Mass reduction Surgery None or not specified Postoperatively the patient did well. Galactorrhea and headaches disappeared; no hormonal replacement therapy was necessary. Postoperatively the patient did well. Galactorrhea and headaches disappeared; no hormonal replacement therapy was necessary.
16 Mass reduction Surgery None or not specified 8 months after surgery menses returned and PRL normalized. 0 8 months after surgery menses returned and PRL normalized.
18 Mass reduction Surgery None or not specified Postoperatively she developed diabetes insipidus, which requires replacement with desmopressin Postoperatively she developed diabetes insipidus, which requires replacement with desmopressin
183 Mass reduction Surgery None or not specified No recurrence at 20 months post-surgery 1 No recurrence at 20 months post-surgery
182 Mass reduction Surgery None or not specified No recurrence at 104 months post-surgery. 8 No recurrence at 104 months post-surgery.
181 Mass reduction Surgery None or not specified No recurrence at 43 months post-surgery 3 No recurrence at 43 months post-surgery
386 Mass reduction Surgery None or not specified Patient received 4 cycles of chemotherapy. One years later the patient did not receive any pituitary hormone replacement. 1 Patient received 4 cycles of chemotherapy. One years later the patient did not receive any pituitary hormone replacement.
54 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Postoperatively visual fields improved and galactorrhea ceased. She developed diabetes insipidus that required desmopressin. She also was treated with hydrocortisone and thyroxine. Postoperatively visual fields improved and galactorrhea ceased. She developed diabetes insipidus that required desmopressin. She also was treated with hydrocortisone and thyroxine.
267 Mass reduction and hormone replacement Surgery Glucocorticoids Headaches and nausea resolved after surgery. 2 months post-surgery the patient is well under prednisolone and hydrochloroquine. 0 Headaches and nausea resolved after surgery. 2 months post-surgery the patient is well under prednisolone and hydrochloroquine.
79 Mass reduction and hormone replacement Surgery Glucocorticoids 1 week post-surgery the headaches disappeared and visual fields normalized. 2 years after surgery the patient is asymptotic and requires only steroid replacement therapy. 2 1 week post-surgery the headaches disappeared and visual fields normalized. 2 years after surgery the patient is asymptotic and requires only steroid replacement therapy.
84 Mass reduction Surgery Glucocorticoids After surgery, she began high dose steroid treatment. Visual defects recover. 4 months later, MRI showed reduction of the pituitary mass. Endocrine tests under steroids showed impaired response of GH to the stimuli. PRL and TSH after TRH stimulus were normal. LH and FSH after GnRH showed decreased LH and normal FSH. 0 After surgery, she began high dose steroid treatment. Visual defects recover. 4 months later, MRI showed reduction of the pituitary mass. Endocrine tests under steroids showed impaired response of GH to the stimuli. PRL and TSH after TRH stimulus were normal. LH and FSH after GnRH showed decreased LH and normal FSH.
307 Mass reduction Surgery None or not specified Patient was well 2.5 years post-surgery, with normal pituitary function. 2 Patient was well 2.5 years post-surgery, with normal pituitary function.
244 Mass reduction and hormone replacement Surgery Glucocorticoids Patient required replacement therapy with glucocorticoids. 2 months after surgery the serum FT4 levels normalized. At 14 months, MRI showed spontaneous resolution of the mass. The patient then became pregnant and delivered a healthy full-term, child. Post-partum, steroid were the only therapy required. 1 Patient required replacement therapy with glucocorticoids. 2 months after surgery the serum FT4 levels normalized. At 14 months, MRI showed spontaneous resolution of the mass. The patient then became pregnant and delivered a healthy full-term, child. Post-partum, steroid were the only therapy required.
168 Mass reduction Surgery None or not specified Visual fields improved. 6 months post surgery the pituitary function was normal. 0 Visual fields improved. 6 months post surgery the pituitary function was normal.
72 Mass reduction and hormone replacement Surgery Glucocorticoids Field defects resolved promptly after surgery. 1 year after surgery the patient is well under cortisol replacement therapy. 1 Field defects resolved promptly after surgery. 1 year after surgery the patient is well under cortisol replacement therapy.
112 Mass reduction and hormone replacement Surgery Glucocorticoids After surgery she developed permanent secondary hypocortisolism, which required replacement with cortisone acetate. After surgery she developed permanent secondary hypocortisolism, which required replacement with cortisone acetate.
143 Mass reduction and hormone replacement Surgery Glucocorticoids After delivery and surgery, visual fields improved. She remained amenorrhoic. After delivery and surgery, visual fields improved. She remained amenorrhoic.
190 Mass reduction and hormone replacement Surgery Glucocorticoids Patient did well under desmopressin, which could be removed 6 months post-operatively. At this time MRI showed regression of the pituitary lesion. 2.5 years after the surgery, patient developed bitemporal hemianopsia. Endocrine function was similar to the first presentation (diabetes insipidus, low response of GH to the stimulus). MRI showed a dumbbell, isointense, lesion extending to the optic chiasm. Recurrence of lymphocytic hypophysitis was suspected and therapy with corticosteroid was began. Symptoms disappeared 1 month later and MRI showed reduction of the mass. 2 Patient did well under desmopressin, which could be removed 6 months post-operatively. At this time MRI showed regression of the pituitary lesion. 2.5 years after the surgery, patient developed bitemporal hemianopsia. Endocrine function was similar to the first presentation (diabetes insipidus, low response of GH to the stimulus). MRI showed a dumbbell, isointense, lesion extending to the optic chiasm. Recurrence of lymphocytic hypophysitis was suspected and therapy with corticosteroid was began. Symptoms disappeared 1 month later and MRI showed reduction of the mass.
142 Mass reduction and hormone replacement Surgery Glucocorticoids Visual fields improved quickly after surgery. Pituitary function was unchanged at 18 months of follow-up and repeat MRI scan showed a largely empty sella. 1 Visual fields improved quickly after surgery. Pituitary function was unchanged at 18 months of follow-up and repeat MRI scan showed a largely empty sella.
387 Mass reduction Surgery Glucocorticoids Patient began prednisone (1 mg/kg/day). One month later he was re-hospitalized for the appearance of complete ophthalmoplegia and blindness of the right eye. MRI showed an increased pituitary mass (32x23x30), extending above the diaphragm and completely invading the right cavernous sinus. The original histology block was re-examined with immunostainings for placental alkaline phosphatase and vimentin, which were positive. hCG beta levels were increased in the CSF and normal in serum. The diagnosed was revised as germinoma with reactive lymphocytic hypophysitis. Patient began chemotherapy and radiotherapy. He died 9 months after surgery. 0 Patient began prednisone (1 mg/kg/day). One month later he was re-hospitalized for the appearance of complete ophthalmoplegia and blindness of the right eye. MRI showed an increased pituitary mass (32x23x30), extending above the diaphragm and completely invading the right cavernous sinus. The original histology block was re-examined with immunostainings for placental alkaline phosphatase and vimentin, which were positive. hCG beta levels were increased in the CSF and normal in serum. The diagnosed was revised as germinoma with reactive lymphocytic hypophysitis. Patient began chemotherapy and radiotherapy. He died 9 months after surgery.
188 Mass reduction Surgery None or not specified Patient received replacement therapy with hydrocortisone with prompt resolution of symptoms. 1 year later MRI showed a normal pituitary. Hydrocortisone was discontinued and the patient remains well 2 years after. 2 Patient received replacement therapy with hydrocortisone with prompt resolution of symptoms. 1 year later MRI showed a normal pituitary. Hydrocortisone was discontinued and the patient remains well 2 years after.
108 Mass reduction and hormone replacement Surgery Glucocorticoids She initially refused surgery. A 3-month trial with steroids was attempted with clear improvement of symptoms, endocrine tests and MRI signs. Symptoms and signs however relapsed after 5 months, so the patient underwent surgery and was placed on steroids again. 3 She initially refused surgery. A 3-month trial with steroids was attempted with clear improvement of symptoms, endocrine tests and MRI signs. Symptoms and signs however relapsed after 5 months, so the patient underwent surgery and was placed on steroids again.
156 Mass reduction and hormone replacement Surgery Glucocorticoids The patient was on thyroxine replacement therapy. 2 weeks after surgery he developed nausea, vomiting, weight loss, dizziness. A CRH test showed no re ACTH response, confirming the clinical suspicion of adrenal insufficiency. Patient began hydrocortisone with clinical improvement. 0 The patient was on thyroxine replacement therapy. 2 weeks after surgery he developed nausea, vomiting, weight loss, dizziness. A CRH test showed no re ACTH response, confirming the clinical suspicion of adrenal insufficiency. Patient began hydrocortisone with clinical improvement.
157 Mass reduction and hormone replacement Surgery Glucocorticoids Visual acuity and fields improved after surgery. She required replacement with hydrocortisone. She also developed postoperatively a transient diabetes insipidus. Visual acuity and fields improved after surgery. She required replacement with hydrocortisone. She also developed postoperatively a transient diabetes insipidus.
196 Mass reduction and hormone replacement Surgery Glucocorticoids 1 month after surgery, she developed clinical signs interpreted as meningitis and was hospitalized. Antibiotics were used but without improvement. 3 months after the 1st surgery she changed hospital. Here endocrine assays showed decreased ACTH, cortisol, FSH and LH. ADH was normal. MRI showed a clearly enhanced pituitary mass. She was operated a second time (4 months after the 1st). Histology showed that both the anterior and posterior lobe were infiltrated with lymphocytes, plasma cells and foamy macrophages, with necrosis. Headaches disappeared after the 2nd surgery, but returned 2 months later, along with visual field defects. Imaging showed a pituitary mass. She received prednisolone with disappearance of her symptoms. She is well under steroids and desmopressin replacement. 0 1 month after surgery, she developed clinical signs interpreted as meningitis and was hospitalized. Antibiotics were used but without improvement. 3 months after the 1st surgery she changed hospital. Here endocrine assays showed decreased ACTH, cortisol, FSH and LH. ADH was normal. MRI showed a clearly enhanced pituitary mass. She was operated a second time (4 months after the 1st). Histology showed that both the anterior and posterior lobe were infiltrated with lymphocytes, plasma cells and foamy macrophages, with necrosis. Headaches disappeared after the 2nd surgery, but returned 2 months later, along with visual field defects. Imaging showed a pituitary mass. She received prednisolone with disappearance of her symptoms. She is well under steroids and desmopressin replacement.
184 Mass reduction Surgery None or not specified No recurrence at 35 months post-surgery 2 No recurrence at 35 months post-surgery
335 Mass reduction and hormone replacement Surgery Thyroxine Postoperatively the patient made an uneventful recovery and visual fields improved. She required replacement with thyroxine. Postoperatively the patient made an uneventful recovery and visual fields improved. She required replacement with thyroxine.
284 Mass reduction Surgery None or not specified A diagnosis of lymphocytic infundibulo-neurohypophysitis was made. The patient was discharged on 60 mg prednisolone daily and 5.5 mg methotrexate weekly. At 9 months he is well and MRI showed reduced size of the pituitary and the infundibulum, and the optic chiasm was no longer compressed. 0 A diagnosis of lymphocytic infundibulo-neurohypophysitis was made. The patient was discharged on 60 mg prednisolone daily and 5.5 mg methotrexate weekly. At 9 months he is well and MRI showed reduced size of the pituitary and the infundibulum, and the optic chiasm was no longer compressed.
119 Mass reduction Surgery None or not specified Symptoms completely disappeared after surgery. Delivery was performed at the 33rd week of gestation via cesarean section. 1 year postpartum CT scan showed a normal pituitary and endocrine tests were normal. 1 Symptoms completely disappeared after surgery. Delivery was performed at the 33rd week of gestation via cesarean section. 1 year postpartum CT scan showed a normal pituitary and endocrine tests were normal.
353 Mass reduction Surgery None or not specified
37 Mass reduction Surgery None or not specified Prolactin remained elevated after surgery and hyperesponsive to TRH. The patient refused bromocriptine and opted for serial observation alone. 4 years later the patient was well. Prolactin remained moderately high (54) but the patient continued to refuse bromocriptine 4 Prolactin remained elevated after surgery and hyperesponsive to TRH. The patient refused bromocriptine and opted for serial observation alone. 4 years later the patient was well. Prolactin remained moderately high (54) but the patient continued to refuse bromocriptine
367 Mass reduction and hormone replacement Surgery Glucocorticoids Headache disappeared after surgery. Endocrine function remain unchanged and the patient continued to require corticosteroid replacement. 3 Headache disappeared after surgery. Endocrine function remain unchanged and the patient continued to require corticosteroid replacement.
152 Mass reduction Surgery None or not specified
300 Mass reduction Surgery None or not specified
299 Mass reduction Surgery None or not specified
298 Mass reduction Surgery None or not specified
297 Mass reduction Surgery None or not specified
296 Mass reduction Surgery None or not specified
320 Mass reduction Surgery None or not specified
321 Mass reduction Surgery None or not specified
154 Mass reduction Surgery None or not specified
151 Mass reduction Surgery None or not specified
312 Mass reduction Surgery None or not specified
153 Mass reduction Surgery None or not specified
155 Mass reduction Surgery None or not specified
213 Mass reduction Surgery None or not specified
210 Mass reduction Surgery None or not specified
212 Mass reduction Surgery None or not specified
147 Mass reduction Surgery None or not specified
105 Mass reduction Surgery None or not specified
287 Mass reduction Surgery None or not specified After surgery the patient received prednisone (60 mg/day) for 3 months with symptomatic and radio logic improvement. 3 years after surgery the patient is asymptomatic without therapy. Pituitary stimulation tests were all normal except for a blunted response of GH to hypoglycemia. 3 After surgery the patient received prednisone (60 mg/day) for 3 months with symptomatic and radio logic improvement. 3 years after surgery the patient is asymptomatic without therapy. Pituitary stimulation tests were all normal except for a blunted response of GH to hypoglycemia.
327 Mass reduction Surgery None or not specified
323 Mass reduction Surgery None or not specified
164 Mass reduction Surgery None or not specified Diabetes insipidus gradually improved and desmopressin replacement became unnecessary 6 months after delivery. 0 Diabetes insipidus gradually improved and desmopressin replacement became unnecessary 6 months after delivery.
333 Mass reduction Surgery None or not specified
332 Mass reduction Surgery None or not specified
331 Mass reduction Surgery None or not specified
330 Mass reduction Surgery None or not specified
329 Mass reduction Surgery None or not specified
328 Mass reduction Surgery None or not specified
270 Mass reduction Surgery None or not specified Visual acuity and fields restored after surgery rapidly and completely. Six weeks later she gave birth to a healthy child. 5 months later MRI was normal. At 2 years follow-up vision remained normal and there were no symptoms of pituitary insufficiency. 2 Visual acuity and fields restored after surgery rapidly and completely. Six weeks later she gave birth to a healthy child. 5 months later MRI was normal. At 2 years follow-up vision remained normal and there were no symptoms of pituitary insufficiency.
301 Mass reduction Surgery None or not specified
385 Mass reduction Surgery None or not specified Patient received four cycles of chemotherapy. 1.5 years later the patient was not receiving hormone replacement 1 Patient received four cycles of chemotherapy. 1.5 years later the patient was not receiving hormone replacement
302 Mass reduction Surgery None or not specified
322 Mass reduction Surgery None or not specified
318 Mass reduction Surgery None or not specified
324 Mass reduction Surgery None or not specified
116 Mass reduction Surgery None or not specified
317 Mass reduction Surgery None or not specified
314 Mass reduction Surgery None or not specified
313 Mass reduction Surgery None or not specified
338 Mass reduction Surgery None or not specified
326 Mass reduction Surgery None or not specified
69 Mass reduction Surgery None or not specified 2 months post-partum CT showed complete normalization. At 7 months post-partum the patient demonstrated full recovery of her pituitary axes. She was clinically and biochemically well for the next 18 months. 1 2 months post-partum CT showed complete normalization. At 7 months post-partum the patient demonstrated full recovery of her pituitary axes. She was clinically and biochemically well for the next 18 months.
201 Mass reduction Surgery None or not specified Visual disturbances gradually improved. No recurrence was noted in the ensuing 5 years 5 Visual disturbances gradually improved. No recurrence was noted in the ensuing 5 years
351 Mass reduction Surgery None or not specified Visual acuity and fields returned to normal in 2 weeks. Prednisone was tapered, but vision declined again in the left eye with worsening of the bitemporal hemianopsia, so prednisone was increased again. Patient delivered almost at term, vaginally. Two weeks post-partum the sellar was 1 x 1 x 1 cm, without mass effect. Prednisone was successfully tapered after delivery. Her endocrinological abnormalities normalized within 6 months. She had a second, uncomplicated pregnancy 2 years later. 2 Visual acuity and fields returned to normal in 2 weeks. Prednisone was tapered, but vision declined again in the left eye with worsening of the bitemporal hemianopsia, so prednisone was increased again. Patient delivered almost at term, vaginally. Two weeks post-partum the sellar was 1 x 1 x 1 cm, without mass effect. Prednisone was successfully tapered after delivery. Her endocrinological abnormalities normalized within 6 months. She had a second, uncomplicated pregnancy 2 years later.
189 Mass reduction Surgery None or not specified No complication, need for therapy or recurrence several weeks after surgery. 0 No complication, need for therapy or recurrence several weeks after surgery.
187 Mass reduction Surgery None or not specified No recurrence at 44 months post-surgery 3 No recurrence at 44 months post-surgery
233 Mass reduction Surgery None or not specified No complications after surgery. 1 week later she was fine, PRL decreased (68). 5 months later she was fine without therapy 0 No complications after surgery. 1 week later she was fine, PRL decreased (68). 5 months later she was fine without therapy
279 Mass reduction Surgery None or not specified Headaches, galactorrhea and amenorrhea resolved. 3 months post-surgery the MRI was normal. No requirement for hormone replacement after 6 years of follow-up. 6 Headaches, galactorrhea and amenorrhea resolved. 3 months post-surgery the MRI was normal. No requirement for hormone replacement after 6 years of follow-up.
202 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Visual fields improved after surgery. The patient is doing well on hydrocortisone replacement and desiccated thyroid hormone. Visual fields improved after surgery. The patient is doing well on hydrocortisone replacement and desiccated thyroid hormone.
214 Mass reduction Surgery None or not specified
269 Mass reduction Surgery None or not specified
345 Mass reduction Surgery None or not specified Headache and ocular pain disappeared after surgery. No complications. Five months after surgery her hormonal levels had normalized without need for hormone replacement therapy. A follow-up MRI showed no recurrence. No pain or medication or hormone replacement 0 Headache and ocular pain disappeared after surgery. No complications. Five months after surgery her hormonal levels had normalized without need for hormone replacement therapy. A follow-up MRI showed no recurrence. No pain or medication or hormone replacement
43 Mass reduction Surgery None or not specified 1 year post-surgery the pituitary function had recovered; the patient required no hormonal replacement and had a normal menstrual cycle. 1 1 year post-surgery the pituitary function had recovered; the patient required no hormonal replacement and had a normal menstrual cycle.
253 Mass reduction Surgery None or not specified After surgery, visual disturbances improved and the patient was discharged. 2 months later MRI showed disappearance of the pituitary lesion and normal pituitary size. Endocrine tests showed normalization of the ACTH response to CRH and of gonadotropins to GnRH. PRL was still elevated. 5 months later imaging and endocrine tests were normal. 0 After surgery, visual disturbances improved and the patient was discharged. 2 months later MRI showed disappearance of the pituitary lesion and normal pituitary size. Endocrine tests showed normalization of the ACTH response to CRH and of gonadotropins to GnRH. PRL was still elevated. 5 months later imaging and endocrine tests were normal.
61 Mass reduction Surgery None or not specified The anterior pituitary function improved after surgery and the patient did not require replacement therapy. She developed, however, diabetes insipidus controlled by desmopressin, which disappeared 1 month after the operation 0 The anterior pituitary function improved after surgery and the patient did not require replacement therapy. She developed, however, diabetes insipidus controlled by desmopressin, which disappeared 1 month after the operation
73 Mass reduction Surgery None or not specified Recovery after surgery was uneventful and the patient required no medication for the next 9 months. She then developed pulmonary sarcoidosis and began prednisone. 1 Recovery after surgery was uneventful and the patient required no medication for the next 9 months. She then developed pulmonary sarcoidosis and began prednisone.
74 Mass reduction Surgery None or not specified Three months after surgery she became pregnant and delivered a healthy full-term baby. Normal pituitary function and CT scan post-partum. 1 Three months after surgery she became pregnant and delivered a healthy full-term baby. Normal pituitary function and CT scan post-partum.
75 Mass reduction Surgery None or not specified 3 months after surgery the patient became pregnant and delivered a full-term baby 11 months after surgery. 4 months postpartum MRI showed a normal pituitary and PRL was normal 1 3 months after surgery the patient became pregnant and delivered a full-term baby 11 months after surgery. 4 months postpartum MRI showed a normal pituitary and PRL was normal
31 Mass reduction Surgery None or not specified Her postoperative course was uncomplicated. She conceived a second time and was able to carry pregnancy to term. No evidence of new pituitary or recurrent thyroid abnormalities was found during that pregnancy or after delivery. 1 Her postoperative course was uncomplicated. She conceived a second time and was able to carry pregnancy to term. No evidence of new pituitary or recurrent thyroid abnormalities was found during that pregnancy or after delivery.
131 Mass reduction Surgery None or not specified 6 months after surgery the patient had normal pituitary function and normal MRI findings. Follow-up at 19 months also showed no evidence of recurrence of lymphocytic hypophysitis. 1 6 months after surgery the patient had normal pituitary function and normal MRI findings. Follow-up at 19 months also showed no evidence of recurrence of lymphocytic hypophysitis.
286 Mass reduction Surgery None or not specified Postoperatively she stopped nursing, followed by return of her menses. Four months after surgery, pituitary function testing showed excellent residual pituitary function. Prolactin level was almost completely normal. 0 Postoperatively she stopped nursing, followed by return of her menses. Four months after surgery, pituitary function testing showed excellent residual pituitary function. Prolactin level was almost completely normal.
130 Mass reduction Surgery None or not specified
36 Mass reduction Surgery None or not specified Postoperative course was uneventful, except for a transient diabetes insipidus. Postoperative course was uneventful, except for a transient diabetes insipidus.
315 Mass reduction Surgery None or not specified
215 Mass reduction Surgery None or not specified
25 Mass reduction Surgery None or not specified
44 Mass reduction Surgery None or not specified Postoperatively the patient developed diabetes insipidus Postoperatively the patient developed diabetes insipidus
67 Mass reduction Surgery None or not specified
126 Mass reduction Surgery None or not specified
146 Mass reduction Surgery None or not specified
308 Mass reduction Surgery None or not specified Patient is well with normal pituitary function 6.5 years after surgery. 6 Patient is well with normal pituitary function 6.5 years after surgery.
129 Mass reduction Surgery None or not specified
337 Mass reduction Surgery None or not specified Prednisone was started at 70 mg/d with a spectacular improvement. It was tapered progressively over 6 months thereafter and replaced by hydrocortisone 30 mg/d. Since that time, no relapse was noted by the patient. At a recent follow up, she was doing well on hormonal replacement therapy. The last MRI, 9 years later, shows a small pituitary gland with evidence of a partial empty sella turcica. 9 Prednisone was started at 70 mg/d with a spectacular improvement. It was tapered progressively over 6 months thereafter and replaced by hydrocortisone 30 mg/d. Since that time, no relapse was noted by the patient. At a recent follow up, she was doing well on hormonal replacement therapy. The last MRI, 9 years later, shows a small pituitary gland with evidence of a partial empty sella turcica.
144 Mass reduction Surgery None or not specified Visual fields improved after surgery. Visual fields improved after surgery.
145 Mass reduction Surgery None or not specified
127 Mass reduction Surgery None or not specified
285 Mass reduction Surgery None or not specified After surgery, a short period of transient diabetes insipidus was followed by uneventful recovery. After surgery, a short period of transient diabetes insipidus was followed by uneventful recovery.
352 Mass reduction Surgery None or not specified 3 months after surgery her visual acuity had improved. 0 3 months after surgery her visual acuity had improved.
185 Mass reduction Surgery None or not specified No recurrence at 10 months post-surgery 0 No recurrence at 10 months post-surgery
349 Mass reduction Surgery None or not specified Patient did well on cortisol replacement and delivered at term an healthy child. Three months post-partum visual fields normalized, MRI showed no evidence of residual mass, and she did not need hormone replacement. 0 Patient did well on cortisol replacement and delivered at term an healthy child. Three months post-partum visual fields normalized, MRI showed no evidence of residual mass, and she did not need hormone replacement.
19 Mass reduction Surgery None or not specified Postoperatively her visual fields normalized. Postoperatively her visual fields normalized.
128 Mass reduction Surgery None or not specified
236 Mass reduction and hormone replacement Surgery More than two hormones Patient received high methylprednisolone iv pulses. 3 years post-surgery: normalization of gonadotropins and GH. ACTH and PRL still impaired. Shrinkage of sellar content nearly to an empty sella; shrinkage of the thickened pituitary stalk. 3 Patient received high methylprednisolone iv pulses. 3 years post-surgery: normalization of gonadotropins and GH. ACTH and PRL still impaired. Shrinkage of sellar content nearly to an empty sella; shrinkage of the thickened pituitary stalk.
229 Mass reduction and hormone replacement Surgery More than two hormones Patient required complete hormonal replacement 1 Patient required complete hormonal replacement
230 Mass reduction and hormone replacement Surgery More than two hormones Patient required complete hormonal replacement 1 Patient required complete hormonal replacement
124 Mass reduction and hormone replacement Surgery More than two hormones The patient is well under thyroxine, hydrocortisone and DDAVP The patient is well under thyroxine, hydrocortisone and DDAVP
82 Mass reduction and hormone replacement Surgery More than two hormones Visual fields defects disappeared and, 2 weeks after surgery, MRI showed disappearance of the pituitary mass. She developed panhypopituitarism and required replacement with thyroxine, prednisone and desmopressin 0 Visual fields defects disappeared and, 2 weeks after surgery, MRI showed disappearance of the pituitary mass. She developed panhypopituitarism and required replacement with thyroxine, prednisone and desmopressin
80 Mass reduction and hormone replacement Surgery More than two hormones The visual acuity deteriorated in the immediate postoperative period. A healthy female infant was delivered near term by cesarean section. The patient remained on anterior pituitary hormone replacement therapy. The visual acuity deteriorated in the immediate postoperative period. A healthy female infant was delivered near term by cesarean section. The patient remained on anterior pituitary hormone replacement therapy.
113 Mass reduction and hormone replacement Surgery More than two hormones Patient is doing well on replacement doses of thyroxine, prednisolone and estrogen-progesterone. Patient is doing well on replacement doses of thyroxine, prednisolone and estrogen-progesterone.
66 Mass reduction and hormone replacement Surgery More than two hormones Patient required replacement with thyroxine, cortisone acetate and testosterone (begun 3 months before surgery). CT scan performed 3 months after surgery showed a very small amount of residual tissue, disproportionately small for the size of the original biopsy taken. 0 Patient required replacement with thyroxine, cortisone acetate and testosterone (begun 3 months before surgery). CT scan performed 3 months after surgery showed a very small amount of residual tissue, disproportionately small for the size of the original biopsy taken.
246 Mass reduction and hormone replacement Surgery More than two hormones Patient improved with steroids and hormone substitution therapy. No recurrence two years later. 2 Patient improved with steroids and hormone substitution therapy. No recurrence two years later.
228 Mass reduction and hormone replacement Surgery More than two hormones Patient required complete hormonal replacement 5 Patient required complete hormonal replacement
311 Mass reduction and hormone replacement Surgery More than two hormones Patient experienced recurrence of visual field defects and was operated a second time (transphenoidal surgery). The second operation showed again creamy material. Patient continued to have panhypopituitarism 4 years after surgery. 4 Patient experienced recurrence of visual field defects and was operated a second time (transphenoidal surgery). The second operation showed again creamy material. Patient continued to have panhypopituitarism 4 years after surgery.
383 Mass reduction Surgery More than two hormones The patient is well 2 years on cortisone, thyroxine and desmopressin replacement therapy, 2 years after surgery 2 The patient is well 2 years on cortisone, thyroxine and desmopressin replacement therapy, 2 years after surgery
104 Mass reduction and hormone replacement Surgery More than two hormones 4 years after surgery, the patient was well with glucocorticoids and desmopressin replacement. 4 4 years after surgery, the patient was well with glucocorticoids and desmopressin replacement.
245 Mass reduction and hormone replacement Surgery More than two hormones Visual fields improved. Endocrine tests showed persistence of hypopituitarism including diabetes insipidus Visual fields improved. Endocrine tests showed persistence of hypopituitarism including diabetes insipidus
50 Mass reduction and hormone replacement Surgery More than two hormones Postoperatively the patient required hormonal replacement with T4, cortisone acetate, and DDAVP 2 Postoperatively the patient required hormonal replacement with T4, cortisone acetate, and DDAVP
364 Mass reduction Surgery More than two hormones Headache disappeared after surgery. Patient continued to require replacement with corticosteroid, thyroxine and estrogen. She experienced recurrent intractable headache 9 months after surgery. She had shown poor compliance with her steroid medication and MRI imaging showed a residual sellar lesion without suprasellar extension. No repeated surgery was required; symptoms improved with regular steroid replacement. 2 Headache disappeared after surgery. Patient continued to require replacement with corticosteroid, thyroxine and estrogen. She experienced recurrent intractable headache 9 months after surgery. She had shown poor compliance with her steroid medication and MRI imaging showed a residual sellar lesion without suprasellar extension. No repeated surgery was required; symptoms improved with regular steroid replacement.
96 Mass reduction and hormone replacement Surgery More than two hormones One month after surgery she developed secondary hypothyroidism. One year after surgery, the patient is well under replacement therapy with desmopressin (DDAVP), thyroxine and estrogen/progesterone. 1 One month after surgery she developed secondary hypothyroidism. One year after surgery, the patient is well under replacement therapy with desmopressin (DDAVP), thyroxine and estrogen/progesterone.
111 Mass reduction and hormone replacement Surgery More than two hormones Patient resumed fully active life with tailored pituitary replacement therapy Patient resumed fully active life with tailored pituitary replacement therapy
226 Mass reduction and hormone replacement Surgery More than two hormones Patient required complete hormonal replacement 1 Patient required complete hormonal replacement
217 Mass reduction and hormone replacement Surgery More than two hormones The patient is well under thyroxine, prednisone, estrogen/progesterone and desmopressin. Prolactin levels normalized. TSH became undetectable 0 The patient is well under thyroxine, prednisone, estrogen/progesterone and desmopressin. Prolactin levels normalized. TSH became undetectable
65 Mass reduction and hormone replacement Surgery More than two hormones Visual fields improved. Patient developed diabetes insipidus, requiring desmopressin replacement, and anterior hypopituitarism requiring replacement with thyroxine, cortisone acetate and estrogen/progesterone. 0 Visual fields improved. Patient developed diabetes insipidus, requiring desmopressin replacement, and anterior hypopituitarism requiring replacement with thyroxine, cortisone acetate and estrogen/progesterone.
70 Mass reduction and hormone replacement Surgery More than two hormones Visual fields normalized post-surgery. She requires replacement with thyroxine, hydrocortisone, estrogen/progesterone and desmopressin. Visual fields normalized post-surgery. She requires replacement with thyroxine, hydrocortisone, estrogen/progesterone and desmopressin.
235 Mass reduction and hormone replacement Surgery More than two hormones Patient received high methylprednisolone iv pulses. 38 months post-surgery: no improvement of pituitary function. Slight shrinkage of enlarged sellar content and pituitary stalk. 3 Patient received high methylprednisolone iv pulses. 38 months post-surgery: no improvement of pituitary function. Slight shrinkage of enlarged sellar content and pituitary stalk.
115 Mass reduction and hormone replacement Surgery More than two hormones Patient required replacement therapy with thyroxine, hydrocortisone, estrogen/progestin combination, and low doses of desmopressin. 6 years later the patient was referred to center for infertility. MRI at this time showed an empty sella with some remnant of hypophyseal tissue. Ovulation was induced with human menopausal gonadotropin and hCG was initiated. She was able to conceived and carry the pregnancy up to the 38th week, when a cesarean section was performed for oligohydramnios. Only thyroxine and desmopressin replacement were increased during pregnancy. She was able to breast feed for 3 months. MRI performed 3 months post-partum showed no change (published by Verdu et al in 1998) 6 Patient required replacement therapy with thyroxine, hydrocortisone, estrogen/progestin combination, and low doses of desmopressin. 6 years later the patient was referred to center for infertility. MRI at this time showed an empty sella with some remnant of hypophyseal tissue. Ovulation was induced with human menopausal gonadotropin and hCG was initiated. She was able to conceived and carry the pregnancy up to the 38th week, when a cesarean section was performed for oligohydramnios. Only thyroxine and desmopressin replacement were increased during pregnancy. She was able to breast feed for 3 months. MRI performed 3 months post-partum showed no change (published by Verdu et al in 1998)
17 Mass reduction and hormone replacement Surgery More than two hormones Post-surgery she developed diabetes insipidus and she required hormonal replacement for her panhypopituitarism Post-surgery she developed diabetes insipidus and she required hormonal replacement for her panhypopituitarism
178 Mass reduction and hormone replacement Surgery More than two hormones Patient required hormone replacement therapy. 0 Patient required hormone replacement therapy.
21 Mass reduction and hormone replacement Surgery More than two hormones Patient required replacement with thyroxine and steroids, and estrogen/progesterone Patient required replacement with thyroxine and steroids, and estrogen/progesterone
384 Mass reduction Surgery More than two hormones 5 months after surgery she complained of visual loss and headaches. Patient underwent a second surgery (transcranial). Histology showed again lymphocytic hypophysitis. No tumor was seen. Five months after the second operation MRI showed multiple metastatic cerebral lesions. Patient underwent a third surgery (open craniotomy). Histology showed a germinoma. 1 5 months after surgery she complained of visual loss and headaches. Patient underwent a second surgery (transcranial). Histology showed again lymphocytic hypophysitis. No tumor was seen. Five months after the second operation MRI showed multiple metastatic cerebral lesions. Patient underwent a third surgery (open craniotomy). Histology showed a germinoma.
361 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Her visual fields improved and remained stable at five months after surgery. 0 Her visual fields improved and remained stable at five months after surgery.
90 Mass reduction and hormone replacement Surgery More than two hormones Post-operatively the patient developed diabetes insipidus, which however resolved completely. The patient was discharged on thyroxine, cortisol and testosterone. An MRI scan performed 6 months after surgery showed no change in the size of the pituitary gland or the right cavernous sinus involvement. 0 Post-operatively the patient developed diabetes insipidus, which however resolved completely. The patient was discharged on thyroxine, cortisol and testosterone. An MRI scan performed 6 months after surgery showed no change in the size of the pituitary gland or the right cavernous sinus involvement.
76 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Several of the patient's symptoms resolved after surgery, except for diabetes insipidus and impotence. Testosterone injections were started. CT scan 7 months after surgery showed a pituitary markedly decreased in size. 2 years after surgery patient continued to required desmopressin and testosterone. 2 Several of the patient's symptoms resolved after surgery, except for diabetes insipidus and impotence. Testosterone injections were started. CT scan 7 months after surgery showed a pituitary markedly decreased in size. 2 years after surgery patient continued to required desmopressin and testosterone.
227 Mass reduction and hormone replacement Surgery More than two hormones Patient required complete hormonal replacement 1 Patient required complete hormonal replacement
41 Mass reduction and hormone replacement Surgery More than two hormones Patient required replacement therapy with thyroxine, hydrocortisone and testosterone. No diabetes insipidus developed. Patient required replacement therapy with thyroxine, hydrocortisone and testosterone. No diabetes insipidus developed.
52 Mass reduction and hormone replacement Surgery More than two hormones Within 1 year post-surgery the patient developed hypopituitarism requiring replacement therapy. 1 Within 1 year post-surgery the patient developed hypopituitarism requiring replacement therapy.
114 Mass reduction and hormone replacement Surgery More than two hormones After surgery the patient required replacement therapy with thyroxine, hydrocortisone and DDAVP. After surgery the patient required replacement therapy with thyroxine, hydrocortisone and DDAVP.
123 Mass reduction and hormone replacement Surgery Just desmopressin Diabetes insipidus persisted after surgery. She continued to receive desmopressin. Also the dysfunction of the anterior pituitary remained when assessed 3 weeks after the surgery. 0 Diabetes insipidus persisted after surgery. She continued to receive desmopressin. Also the dysfunction of the anterior pituitary remained when assessed 3 weeks after the surgery.
346 Mass reduction and hormone replacement Surgery Just desmopressin No complications after surgery. 1 week later, endocrine tests showed hypopituitarism. The patient began therapy with thyroxine, prednisolone, conjugated estrogens and progesterone. 0 No complications after surgery. 1 week later, endocrine tests showed hypopituitarism. The patient began therapy with thyroxine, prednisolone, conjugated estrogens and progesterone.
39 Mass reduction and hormone replacement Surgery Just desmopressin After surgery the patient developed diabetes insipidus. 3 months after delivery menses returned but she was still unable to lactate 0 After surgery the patient developed diabetes insipidus. 3 months after delivery menses returned but she was still unable to lactate
260 Mass reduction and hormone replacement Surgery Just desmopressin Prolactin normalized after surgery and galactorrhea disappeared. She developed however diabetes insipidus, which required replacement with desmopressin. Prolactin normalized after surgery and galactorrhea disappeared. She developed however diabetes insipidus, which required replacement with desmopressin.
262 Mass reduction and hormone replacement Surgery Just desmopressin 1 year after surgery she is well under desmopressin replacement. 1 1 year after surgery she is well under desmopressin replacement.
271 Mass reduction and hormone replacement Surgery Just desmopressin The patient required desmopressin replacement. 3 years after surgery, MRI was normal and all anterior pituitary hormones were in the normal range. 3 The patient required desmopressin replacement. 3 years after surgery, MRI was normal and all anterior pituitary hormones were in the normal range.
259 Mass reduction and hormone replacement Surgery Just desmopressin Prolactin normalized after surgery, but diabetes insipidus continued and required replacement with desmopressin. Prolactin normalized after surgery, but diabetes insipidus continued and required replacement with desmopressin.
107 Mass reduction and hormone replacement Surgery More than two hormones After surgery patient received no specific therapy besides hormone replacement. 1.5 years later, MRI showed a progressive and dramatic improvement, with return to a normal appearing pituitary and stalk. 1 After surgery patient received no specific therapy besides hormone replacement. 1.5 years later, MRI showed a progressive and dramatic improvement, with return to a normal appearing pituitary and stalk.
77 Mass reduction and hormone replacement Surgery Just desmopressin The patient did well. One year after surgery she had normal menses, normal prolactin and no drugs other than desmopressin. MRI showed no residual mass. 17 months after surgery her clinical condition was stable. 1 The patient did well. One year after surgery she had normal menses, normal prolactin and no drugs other than desmopressin. MRI showed no residual mass. 17 months after surgery her clinical condition was stable.
38 Mass reduction and hormone replacement Surgery Just desmopressin After surgery she developed diabetes insipidus, treated with desmopressin. 10 months post surgery, CT scan showed a reduction of the mass. 0 After surgery she developed diabetes insipidus, treated with desmopressin. 10 months post surgery, CT scan showed a reduction of the mass.
93 Mass reduction and hormone replacement Surgery Just desmopressin Patient is well with desmopressin replacement. A follow-up MRI showed shrinkage of the posterior lobe. Patient is well with desmopressin replacement. A follow-up MRI showed shrinkage of the posterior lobe.
91 Mass reduction and hormone replacement Surgery Just desmopressin Patient is well with desmopressin replacement. A follow-up MRI showed shrinkage of the pituitary stalk. Patient is well with desmopressin replacement. A follow-up MRI showed shrinkage of the pituitary stalk.
134 Mass reduction and hormone replacement Surgery Estrogen or androgen replacement Patient is well under estrogen replacement. She does not require thyroxine or glucocorticoid. A CT scan 3 year later showed no evidence of recurrence 3 Patient is well under estrogen replacement. She does not require thyroxine or glucocorticoid. A CT scan 3 year later showed no evidence of recurrence
370 Mass reduction and hormone replacement Surgery Estrogen or androgen replacement Headache disappeared after surgery. Libido and energy improved. Patient continued to require testosterone replacement. 0 Headache disappeared after surgery. Libido and energy improved. Patient continued to require testosterone replacement.
206 Mass reduction and hormone replacement Surgery Estrogen or androgen replacement Replacement therapy with testosterone Replacement therapy with testosterone
380 Mass reduction Surgery Estrogen or androgen replacement Radiotherapy was performed after the hypophysectomy because of the concomitant diagnosis of adenoma. The patient is well under testosterone replacement. This is the first report of hypophysitis occurring with a functioning GH adenoma. The patient also had type 1 DM. Patient required androgen replacement. CT scan showed empty sella. Radiotherapy was performed after the hypophysectomy because of the concomitant diagnosis of adenoma. The patient is well under testosterone replacement. This is the first report of hypophysitis occurring with a functioning GH adenoma. The patient also had type 1 DM. Patient required androgen replacement. CT scan showed empty sella.
98 Mass reduction and hormone replacement Surgery Just desmopressin After surgery the patient required replacement therapy with desmopressin. Hydrocortisone was began after surgery and gradually withdrawn over the following 6 months. 0 After surgery the patient required replacement therapy with desmopressin. Hydrocortisone was began after surgery and gradually withdrawn over the following 6 months.
192 Mass reduction and hormone replacement Surgery Just desmopressin Patient required desmopressin replacement therapy. Patient required desmopressin replacement therapy.
377 Mass reduction Surgery More than two hormones Patient had a complete pituitary insufficiency requiring replacement 11 years after surgery. 11 Patient had a complete pituitary insufficiency requiring replacement 11 years after surgery.
381 Mass reduction Surgery More than two hormones Headaches resolved 1 month after surgery. Patient required replacement therapy with hydrocortisone, thyroxine and estrogen/progestin. 1 year after surgery CT scan showed residual tissue in the pituitary fossa, which was felt to represent the muscle graft inserted. 1 Headaches resolved 1 month after surgery. Patient required replacement therapy with hydrocortisone, thyroxine and estrogen/progestin. 1 year after surgery CT scan showed residual tissue in the pituitary fossa, which was felt to represent the muscle graft inserted.
247 Mass reduction and hormone replacement Surgery Just desmopressin After surgery, PRL levels normalized and galactorrhea disappeared. The patient needed desmopressin to control her diabetes insipidus. After surgery, PRL levels normalized and galactorrhea disappeared. The patient needed desmopressin to control her diabetes insipidus.
216 Mass reduction and hormone replacement Surgery Just desmopressin The postoperative course was uneventful. The patient is well under desmopressin replacement therapy 17 months after surgery. MRI showed no recurrence of the lesion. 1 The postoperative course was uneventful. The patient is well under desmopressin replacement therapy 17 months after surgery. MRI showed no recurrence of the lesion.
165 Mass reduction and hormone replacement Surgery Just desmopressin Patient requires replacement therapy with desmopressin. Patient requires replacement therapy with desmopressin.
382 Mass reduction Surgery Just desmopressin 30 months after surgery the patient is well with desmopressin replacement. 7 years after surgery MRI showed no recurrence and anterior pituitary function was normal. 7 30 months after surgery the patient is well with desmopressin replacement. 7 years after surgery MRI showed no recurrence and anterior pituitary function was normal.
92 Mass reduction and hormone replacement Surgery Just desmopressin Patient is well with desmopressin replacement. A follow-up MRI showed shrinkage of the pituitary stalk. Patient is well with desmopressin replacement. A follow-up MRI showed shrinkage of the pituitary stalk.
249 Mass reduction and hormone replacement Surgery Just desmopressin After 2 months the patient is well with desmopressin replacement therapy. 0 After 2 months the patient is well with desmopressin replacement therapy.
334 Mass reduction and hormone replacement Surgery Just desmopressin Over the next 4 months, there was a dramatic reduction in size and, finally, disappearance of the mass, with improvement in the vision of her right eye to an acuity of 6/18, though with persistence of the macular sparing temporal field loss. The vision in the left eye remained unchanged. This improvement persisted after the dexamethasone was gradually withdrawn. She remains on cortisone, levothyroxine sodium, and desmopressin nasal drops, and is followed by the Endocrine as well as Neurosurgical outpatient departments. 0 Over the next 4 months, there was a dramatic reduction in size and, finally, disappearance of the mass, with improvement in the vision of her right eye to an acuity of 6/18, though with persistence of the macular sparing temporal field loss. The vision in the left eye remained unchanged. This improvement persisted after the dexamethasone was gradually withdrawn. She remains on cortisone, levothyroxine sodium, and desmopressin nasal drops, and is followed by the Endocrine as well as Neurosurgical outpatient departments.
195 Mass reduction and hormone replacement Surgery Just desmopressin The patient required replacement with desmopressin. MRI performed 2 months after surgery showed reduction of the thickened pituitary stalk. The hyperintensity of the posterior lobe had not returned. 0 The patient required replacement with desmopressin. MRI performed 2 months after surgery showed reduction of the thickened pituitary stalk. The hyperintensity of the posterior lobe had not returned.
88 Mass reduction and hormone replacement Surgery Just desmopressin Patient required replacement therapy with desmopressin. 3.5 years after surgery the patient was well with this therapy. 3 Patient required replacement therapy with desmopressin. 3.5 years after surgery the patient was well with this therapy.
103 Mass reduction and hormone replacement Surgery Just desmopressin Patient required desmopressin replacement Patient required desmopressin replacement
109 Hormone replacement Surgery Just desmopressin Patient began replacement with desmopressin. One year after surgery, imaging showed still enlargement of the stalk. Patient complained of headache. Doctors considered beginning steroids. 1 Patient began replacement with desmopressin. One year after surgery, imaging showed still enlargement of the stalk. Patient complained of headache. Doctors considered beginning steroids.
99 Mass reduction and hormone replacement Surgery Just desmopressin He received prednisolone for 4 months after surgery. He is well since that time under desmopressin replacement. 0 He received prednisolone for 4 months after surgery. He is well since that time under desmopressin replacement.
136 Mass reduction and hormone replacement Surgery Just desmopressin Postoperatively the patient developed diabetes insipidus, requiring desmopressin Postoperatively the patient developed diabetes insipidus, requiring desmopressin
48 Mass reduction and hormone replacement Surgery More than two hormones Postoperatively the patient developed diabetes insipidus, hypothyroidism and hypocortisolism, which required replacement with desmopressin, thyroxine and cortisone acetate. Postoperatively the patient developed diabetes insipidus, hypothyroidism and hypocortisolism, which required replacement with desmopressin, thyroxine and cortisone acetate.
248 Mass reduction and hormone replacement Surgery Just desmopressin The patient did well under desmopressin replacement therapy. The patient did well under desmopressin replacement therapy.
13 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Postoperatively the patient developed diabetes insipidus, but the visual fields recovered almost completely. Two months later she delivered an healthy infant. She was able to lactate, but she required replacement therapy with thyroxine and prednisone. Postoperatively the patient developed diabetes insipidus, but the visual fields recovered almost completely. Two months later she delivered an healthy infant. She was able to lactate, but she required replacement therapy with thyroxine and prednisone.
45 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) The postoperative period was uneventful and the patient remained well with thyroxine and cortisone acetate replacement. CT scan performed 2.5 years later showed no recurrence of the sellar lesion. 2 The postoperative period was uneventful and the patient remained well with thyroxine and cortisone acetate replacement. CT scan performed 2.5 years later showed no recurrence of the sellar lesion.
94 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) 3 months after surgery, the patient was well with thyroxine and hydrocortisone replacement. 0 3 months after surgery, the patient was well with thyroxine and hydrocortisone replacement.
224 Mass reduction and hormone replacement Surgery More than two hormones Patient required complete hormonal replacement 1 Patient required complete hormonal replacement
132 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient was well on thyroxine and hydrocortisone. A repeat CT scan 5 years later showed only a small amount of residual pituitary tissue in a largely empty sella 5 Patient was well on thyroxine and hydrocortisone. A repeat CT scan 5 years later showed only a small amount of residual pituitary tissue in a largely empty sella
237 Mass reduction and hormone replacement Surgery More than two hormones Patient received high methylprednisolone iv pulses. 2 years post-surgery: persistent impairment of gonadotropins, GH and PRL; appearance of diabetes insipidus. 2 Patient received high methylprednisolone iv pulses. 2 years post-surgery: persistent impairment of gonadotropins, GH and PRL; appearance of diabetes insipidus.
89 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) At 39th week of gestation a healthy infant was delivered vaginally. Visual fields improved. 1 year after delivery the patient was well under thyroxine and hydrocortisone replacement therapy. 1 At 39th week of gestation a healthy infant was delivered vaginally. Visual fields improved. 1 year after delivery the patient was well under thyroxine and hydrocortisone replacement therapy.
161 Mass reduction and hormone replacement Surgery More than two hormones The patient is under replacement therapy with hydrocortisone, thyroxine, estrogen/progesterone. 3 months postoperatively she developed also a GH deficiency, which was treated with GH supplementation. 1 year after surgery MRI revealed no signs of recurrence. 0 The patient is under replacement therapy with hydrocortisone, thyroxine, estrogen/progesterone. 3 months postoperatively she developed also a GH deficiency, which was treated with GH supplementation. 1 year after surgery MRI revealed no signs of recurrence.
133 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient requires lifelong therapy with thyroxine and hydrocortisone Patient requires lifelong therapy with thyroxine and hydrocortisone
53 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Postoperative course was uneventful with the exception of the development of diabetes insipidus that responded to desmopressin. She was discharged on thyroxine and hydrocortisone replacement therapy. Three years later she died in an Addisonian crisis due to the lack of compliance with her medicines. Autopsy did not reveal any other endocrine gland involvement. 3 Postoperative course was uneventful with the exception of the development of diabetes insipidus that responded to desmopressin. She was discharged on thyroxine and hydrocortisone replacement therapy. Three years later she died in an Addisonian crisis due to the lack of compliance with her medicines. Autopsy did not reveal any other endocrine gland involvement.
250 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Post-surgery the patient required replacement therapy with thyroxine and hydrocortisone. Post-surgery the patient required replacement therapy with thyroxine and hydrocortisone.
10 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) 10 months post-surgery the patient is well under thyroxine and corticosteroid replacement. 0 10 months post-surgery the patient is well under thyroxine and corticosteroid replacement.
366 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Headache disappeared after surgery. Patient continued to require replacement with corticosteroid and thyroxine. 4 Headache disappeared after surgery. Patient continued to require replacement with corticosteroid and thyroxine.
60 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Visual fields normalize. The patient required replacement therapy with thyroxine and hydrocortisone. Visual fields normalize. The patient required replacement therapy with thyroxine and hydrocortisone.
58 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient required replacement with thyroxine and hydrocortisone. Patient required replacement with thyroxine and hydrocortisone.
166 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Symptoms improved after surgery. 5 months after surgery she conceived again. At the 2nd month of this pregnancy the patient appeared in good general conditions, but tests showed secondary hypothyroidism and hypocortisolism and so she began replacement with thyroxine and hydrocortisone. Delivery was normal. She was unable to lactate. Three months later tests showed no improvement of thyroid and adrenal function. 1 Symptoms improved after surgery. 5 months after surgery she conceived again. At the 2nd month of this pregnancy the patient appeared in good general conditions, but tests showed secondary hypothyroidism and hypocortisolism and so she began replacement with thyroxine and hydrocortisone. Delivery was normal. She was unable to lactate. Three months later tests showed no improvement of thyroid and adrenal function.
62 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Post-surgery the patient continues to require replacement therapy with thyroxine and hydrocortisone. Post-surgery the patient continues to require replacement therapy with thyroxine and hydrocortisone.
280 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) After surgery the patient developed secondary adrenal failure, which required prednisolone therapy. She also received thyroxine replacement therapy After surgery the patient developed secondary adrenal failure, which required prednisolone therapy. She also received thyroxine replacement therapy
68 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) After surgery she required replacement with thyroxine and sex hormones. Visual fields defects improved After surgery she required replacement with thyroxine and sex hormones. Visual fields defects improved
102 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Visual fields improved after surgery. She continued steroids and thyroxine replacement. 0 Visual fields improved after surgery. She continued steroids and thyroxine replacement.
150 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Adrenal and thyroid hormone replacement Adrenal and thyroid hormone replacement
78 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) The patient received hormone replacement therapy (not specified which one). One week later visual fields improved. After 6 months menses returned and vision normalized 0 The patient received hormone replacement therapy (not specified which one). One week later visual fields improved. After 6 months menses returned and vision normalized
175 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient received replacement therapy with hydrocortisone and thyroxine. Visual fields improved and resolved 2 months after delivery. 4 years later the patient delivered her second child, under the replacement therapy. 4 days after the 2nd delivery, MRI showed a shrunk pituitary gland (1 mm high), which indicated empty sella. 4 Patient received replacement therapy with hydrocortisone and thyroxine. Visual fields improved and resolved 2 months after delivery. 4 years later the patient delivered her second child, under the replacement therapy. 4 days after the 2nd delivery, MRI showed a shrunk pituitary gland (1 mm high), which indicated empty sella.
64 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Visual fields improved after surgery, she required replacement with thyroxine and corticosteroids Visual fields improved after surgery, she required replacement with thyroxine and corticosteroids
203 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Visual fields improved after surgery and the patient is doing well on oral hydrocortisone and desiccated thyroid hormone. Visual fields improved after surgery and the patient is doing well on oral hydrocortisone and desiccated thyroid hormone.
310 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient required replacement therapy with prednisolone and thyroxine. Patient required replacement therapy with prednisolone and thyroxine.
14 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) The patient required replacement therapy with thyroxine and hydrocortisone, which was begun before surgery and continued afterward. She also developed postoperatively diabetes insipidus. The patient required replacement therapy with thyroxine and hydrocortisone, which was begun before surgery and continued afterward. She also developed postoperatively diabetes insipidus.
56 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) The patient required replacement with thyroxine and hydrocortisone (began before surgery). After surgery she developed transient diabetes insipidus. The patient required replacement with thyroxine and hydrocortisone (began before surgery). After surgery she developed transient diabetes insipidus.
51 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) The post-operative course was uneventful. Anterior pituitary function tests were repeated but remained unchanged compared to the pre-operative tests. 9 months post-op the patient's thyroid and corticosteroid replacement levels were satisfactory. 0 The post-operative course was uneventful. Anterior pituitary function tests were repeated but remained unchanged compared to the pre-operative tests. 9 months post-op the patient's thyroid and corticosteroid replacement levels were satisfactory.
200 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Post-operatively the patient remained well on thyroxine and prednisone replacement. 0 Post-operatively the patient remained well on thyroxine and prednisone replacement.
83 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient continued desmopressin replacement. 3 months later he complained of oliguria and anorexia, malaise, generalized edema. Endocrine tests showed secondary hypocortisolism. He began hydrocortisone replacement. 4 months after surgery, GH was low, gonadotropins response delayed (normal TSH, PRL and cortisol). Hydrocortisone was stopped 6 months after surgery 0 Patient continued desmopressin replacement. 3 months later he complained of oliguria and anorexia, malaise, generalized edema. Endocrine tests showed secondary hypocortisolism. He began hydrocortisone replacement. 4 months after surgery, GH was low, gonadotropins response delayed (normal TSH, PRL and cortisol). Hydrocortisone was stopped 6 months after surgery
57 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) 3 months after surgery the patient was well under thyroxine and hydrocortisone replacement. 0 3 months after surgery the patient was well under thyroxine and hydrocortisone replacement.
319 Mass reduction Surgery None or not specified
46 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient required replacement therapy with thyroxine and hydrocortisone. She also developed postoperatively diabetes insipidus, which required replacement with desmopressin. Patient required replacement therapy with thyroxine and hydrocortisone. She also developed postoperatively diabetes insipidus, which required replacement with desmopressin.
225 Mass reduction and hormone replacement Surgery Glucocorticoids and thyroixine (or other two hormone combination) Patient required hormonal replacement 4 Patient required hormonal replacement
278 Mass reduction and hormone replacement Surgery More than two hormones 6 months post-operatively she remains panhypopituitaric. 0 6 months post-operatively she remains panhypopituitaric.
186 Mass reduction and hormone replacement Surgery More than two hormones There was a recurrence 1 year post-surgery. So the transphenoidal surgery was repeated a second time 2 There was a recurrence 1 year post-surgery. So the transphenoidal surgery was repeated a second time
106 Mass reduction and hormone replacement Surgery More than two hormones Patient received high-dose prednisone (60 mg/day) for 3 weeks, with clinical improvement of the headache. MRI showed reduction of the pituitary mass. As steroids were tapered, MRI showed a gradual increase in the size of the pituitary. Thus, 9 months after surgery, prednisone was reinstituted. This treatment produced a new improvement of the symptoms and reduction of the pituitary size. 1.67 years after surgery there was a spontaneous regression of the pituitary mass lesion, despite continued reduction of the prednisone to a maintenance dose. 1 Patient received high-dose prednisone (60 mg/day) for 3 weeks, with clinical improvement of the headache. MRI showed reduction of the pituitary mass. As steroids were tapered, MRI showed a gradual increase in the size of the pituitary. Thus, 9 months after surgery, prednisone was reinstituted. This treatment produced a new improvement of the symptoms and reduction of the pituitary size. 1.67 years after surgery there was a spontaneous regression of the pituitary mass lesion, despite continued reduction of the prednisone to a maintenance dose.
291 Mass reduction and hormone replacement Surgery More than two hormones After surgery visual field defects improved. Endocrine tests revealed complete hypopituitarism, with more pronounced hyperprolactinemia and diabetes insipidus. MRI repeated 6 months after surgery showed a residual 5 mm sellar mass. 0 After surgery visual field defects improved. Endocrine tests revealed complete hypopituitarism, with more pronounced hyperprolactinemia and diabetes insipidus. MRI repeated 6 months after surgery showed a residual 5 mm sellar mass.
256 Mass reduction and hormone replacement Surgery More than two hormones After surgery she developed permanent diabetes insipidus, which required replacement with desmopressin. She maintained her global hypopituitarism, which required replacement therapy. 3 years after surgery MRI did not show any residual or recurring inflammatory tissue (empty sella) 3 After surgery she developed permanent diabetes insipidus, which required replacement with desmopressin. She maintained her global hypopituitarism, which required replacement therapy. 3 years after surgery MRI did not show any residual or recurring inflammatory tissue (empty sella)
378 Mass reduction Surgery More than two hormones Patient had a complete pituitary insufficiency requiring replacement 2 years after surgery. 2 Patient had a complete pituitary insufficiency requiring replacement 2 years after surgery.
261 Mass reduction and hormone replacement Surgery More than two hormones Diplopia and panhypopituitarism continued after surgery. He is on replacement with thyroxine, prednisolone and testosterone. Diplopia and panhypopituitarism continued after surgery. He is on replacement with thyroxine, prednisolone and testosterone.
372 Mass reduction and hormone replacement Surgery More than two hormones Hemianopsia disappeared after surgery. Patient continued to require replacement with corticosteroid, thyroxine, growth hormone, testosterone and desmopressin. 0 Hemianopsia disappeared after surgery. Patient continued to require replacement with corticosteroid, thyroxine, growth hormone, testosterone and desmopressin.
265 Mass reduction and hormone replacement Surgery More than two hormones Post-operative course was generally smooth and the child was discharged on day 11. Over the next few years the child required growth hormone, testosterone and thyroxine. Also cortisol at times of stress. Yearly MRIs were performed. MRI 4 years after surgery showed regression of the residual enhancing abnormality. 9 Post-operative course was generally smooth and the child was discharged on day 11. Over the next few years the child required growth hormone, testosterone and thyroxine. Also cortisol at times of stress. Yearly MRIs were performed. MRI 4 years after surgery showed regression of the residual enhancing abnormality.
274 Mass reduction and hormone replacement Surgery More than two hormones Patient began therapy with desmopressin, hydrocortisone estrogens and progesterone, thyroxine. 7 months later hydrocortisone dosage was decreased to 5 mg/day. MRI performed 2 years after surgery showed a pituitary stalk decreased in size and a disappearance of the abnormal gadolinium enhancement. 2 Patient began therapy with desmopressin, hydrocortisone estrogens and progesterone, thyroxine. 7 months later hydrocortisone dosage was decreased to 5 mg/day. MRI performed 2 years after surgery showed a pituitary stalk decreased in size and a disappearance of the abnormal gadolinium enhancement.
254 Mass reduction and hormone replacement Surgery More than two hormones To control her symptoms the patient received stereotactic radiation therapy. The clinical and radiological signs of the lymphocytic hypophysitis improved, while the central diabetes insipidus and panhypopituitarism persisted. 5 months later, MRI showed multiple intracranial lesions identified as germinomas, treated with chemotherapy and radiotherapy. 1 year after completion of this treatment there was no tumor recurrence. She required replacement with desmopressin, thyroxine, hydrocortisone and estradiol. GH replacement to be initiated. 1 To control her symptoms the patient received stereotactic radiation therapy. The clinical and radiological signs of the lymphocytic hypophysitis improved, while the central diabetes insipidus and panhypopituitarism persisted. 5 months later, MRI showed multiple intracranial lesions identified as germinomas, treated with chemotherapy and radiotherapy. 1 year after completion of this treatment there was no tumor recurrence. She required replacement with desmopressin, thyroxine, hydrocortisone and estradiol. GH replacement to be initiated.
275 Mass reduction and hormone replacement Surgery More than two hormones A post-operative MRI showed a reduction of the lesions in the pituitary and the stalk. Panhypopituitarism and diabetes insipidus were treated by hormone replacement therapy. 0 A post-operative MRI showed a reduction of the lesions in the pituitary and the stalk. Panhypopituitarism and diabetes insipidus were treated by hormone replacement therapy.
277 Mass reduction and hormone replacement Surgery More than two hormones 2 years post-operatively she remains panhypopituitaric and has normal vision. 2 2 years post-operatively she remains panhypopituitaric and has normal vision.
336 Mass reduction and hormone replacement Surgery More than two hormones The post-operative course was uneventful. Visual function improved, although a modest reduction in the peripheral visual field persisted. Follow-up MRI 2.5 years after surgery showed loss of volume within the pituitary fossa. Her hypopituitarism and diabetes insipidus required hormone replacement therapy. Five years following the apoplexy she delivered a healthy pair of twins. 5 The post-operative course was uneventful. Visual function improved, although a modest reduction in the peripheral visual field persisted. Follow-up MRI 2.5 years after surgery showed loss of volume within the pituitary fossa. Her hypopituitarism and diabetes insipidus required hormone replacement therapy. Five years following the apoplexy she delivered a healthy pair of twins.
281 Mass reduction and hormone replacement Surgery More than two hormones Post-surgery the patient developed secondary hypothyroidism and worsening of the hyperprolactinemia. 6 months after surgery the patient was well with bromocriptine and estrogen/progesterone, desmopressin and thyroxine replacement therapy 0 Post-surgery the patient developed secondary hypothyroidism and worsening of the hyperprolactinemia. 6 months after surgery the patient was well with bromocriptine and estrogen/progesterone, desmopressin and thyroxine replacement therapy
110 Mass reduction and hormone replacement Surgery More than two hormones Patient resumed fully active life with tailored pituitary replacement therapy Patient resumed fully active life with tailored pituitary replacement therapy
264 Mass reduction and hormone replacement Surgery More than two hormones She received 3 pulse therapies with methylprednisolone to reduce the pituitary swelling. After the second course of pulse therapy MRI showed almost normal pituitary stalk. However diabetes insipidus persisted. The patient remained on desmopressin and prednisone (30 mg per day). Status unchanged 3 months after surgery. 0 She received 3 pulse therapies with methylprednisolone to reduce the pituitary swelling. After the second course of pulse therapy MRI showed almost normal pituitary stalk. However diabetes insipidus persisted. The patient remained on desmopressin and prednisone (30 mg per day). Status unchanged 3 months after surgery.
167 Mass reduction and hormone replacement Surgery More than two hormones After surgery the patient developed mild hyperprolactenemia and low gonadotropins. In addition to the desmopressin replacement, she also received estrogen. 8 months post-surgery, MRI showed decrease of the thickening of the infundibulum. 0 After surgery the patient developed mild hyperprolactenemia and low gonadotropins. In addition to the desmopressin replacement, she also received estrogen. 8 months post-surgery, MRI showed decrease of the thickening of the infundibulum.
341 Mass reduction and hormone replacement Surgery More than two hormones The patient was well under hormone replacement therapy. 0 The patient was well under hormone replacement therapy.
371 Mass reduction and hormone replacement Surgery More than two hormones Hemianopsia disappeared after surgery. Patient continued to require replacement with corticosteroid, thyroxine and desmopressin. 0 Hemianopsia disappeared after surgery. Patient continued to require replacement with corticosteroid, thyroxine and desmopressin.
309 Mass reduction and hormone replacement Surgery More than two hormones Patient developed panhypopituitarism Patient developed panhypopituitarism
170 Mass reduction and hormone replacement Surgery More than two hormones Cystic and bloody liquid was removed from the center of the lesion. Symptoms did not improve too much after surgery, and PRL remained elevated, despite bromocriptine. 3.5 years later headaches reappeared, along with amenorrhea. Endocrine tests showed panhypopituitarism. CT scan showed increased pituitary volume. The patient was operated a second time. Histology this time showed hypophysitis (see above). Symptoms improved after the second surgery. MRI performed 1 month later showed reduction of the pituitary volume. 4 Cystic and bloody liquid was removed from the center of the lesion. Symptoms did not improve too much after surgery, and PRL remained elevated, despite bromocriptine. 3.5 years later headaches reappeared, along with amenorrhea. Endocrine tests showed panhypopituitarism. CT scan showed increased pituitary volume. The patient was operated a second time. Histology this time showed hypophysitis (see above). Symptoms improved after the second surgery. MRI performed 1 month later showed reduction of the pituitary volume.
49 Mass reduction and hormone replacement Surgery More than two hormones One month following delivery and then surgery, pituitary function testing revealed panhypopituitarism. The patient was placed on full hormonal replacement therapy and remains well at 3.5 years follow-up. 3 One month following delivery and then surgery, pituitary function testing revealed panhypopituitarism. The patient was placed on full hormonal replacement therapy and remains well at 3.5 years follow-up.
368 Mass reduction and hormone replacement Surgery More than two hormones Headache and hemianopsia disappeared after surgery. Energy level improved. No changes in the endocrine status and the patient continued to require replacement with corticosteroids, thyroxine, growth hormone and estrogen. 1 Headache and hemianopsia disappeared after surgery. Energy level improved. No changes in the endocrine status and the patient continued to require replacement with corticosteroids, thyroxine, growth hormone and estrogen.
199 Mass reduction and hormone replacement Surgery More than two hormones 3 months after surgery, MRI showed a decrease in stalk thickening, but he continued to have evidence of multiple pituitary hormone deficiencies. 0 3 months after surgery, MRI showed a decrease in stalk thickening, but he continued to have evidence of multiple pituitary hormone deficiencies.
205 Mass reduction and hormone replacement Surgery More than two hormones Replacement therapy with desmopressin, thyroxine, hydrocortisone and testosterone Replacement therapy with desmopressin, thyroxine, hydrocortisone and testosterone
180 Mass reduction and hormone replacement Surgery More than two hormones 21 months from diagnosis MRI shows that the pituitary mass was 9x6x9 mm. Clinically the patient was well under desmopressin replacement and estrogen/progesterone replacement for her hypogonadotropic hypogonadism 1 21 months from diagnosis MRI shows that the pituitary mass was 9x6x9 mm. Clinically the patient was well under desmopressin replacement and estrogen/progesterone replacement for her hypogonadotropic hypogonadism
350 Mass reduction and hormone replacement Surgery More than two hormones Patient was discharged with 60 mg/day prednisone and hormone replacement for panhypopituitarism. Two months later he developed aseptic meningoencephalitis, which required high dose iv methylprednisolone for control. Because of evidence of iatrogenic Cushing's syndrome, azathioprine was used for 5 months with resolution of the headaches. 18 months after suspension of azathioprine, patient was fine under hormone replacement. 2 Patient was discharged with 60 mg/day prednisone and hormone replacement for panhypopituitarism. Two months later he developed aseptic meningoencephalitis, which required high dose iv methylprednisolone for control. Because of evidence of iatrogenic Cushing's syndrome, azathioprine was used for 5 months with resolution of the headaches. 18 months after suspension of azathioprine, patient was fine under hormone replacement.
360 Mass reduction and hormone replacement Surgery More than two hormones Her olfactory function improved, but she remained hypopituitaric with high prolactin, and required continues replacement with thyroxine, prednisolone and estrogens. 0 Her olfactory function improved, but she remained hypopituitaric with high prolactin, and required continues replacement with thyroxine, prednisolone and estrogens.
363 Mass reduction and hormone replacement Surgery More than two hormones Headache and diplopia disappeared after surgery. Patient continued to require replacement therapy with corticosteroid, thyroxine and testosterone. 3 Headache and diplopia disappeared after surgery. Patient continued to require replacement therapy with corticosteroid, thyroxine and testosterone.
365 Mass reduction and hormone replacement Surgery More than two hormones Headache disappeared after surgery. Libido improved. Patient required hormone replacement with corticosteroid, testosterone and growth hormone. 1 Headache disappeared after surgery. Libido improved. Patient required hormone replacement with corticosteroid, testosterone and growth hormone.
276 Mass reduction and hormone replacement Surgery More than two hormones Post-operatively she developed headaches, sinusitis, depression and CSF leak, which required craniotomy to be closed. She had panhypopituitarism. Vision normalized. She has been followed for 10 years. 10 Post-operatively she developed headaches, sinusitis, depression and CSF leak, which required craniotomy to be closed. She had panhypopituitarism. Vision normalized. She has been followed for 10 years.
347 Mass reduction and hormone replacement Surgery More than two hormones Patient did fine with thyroxine, glucocorticoid and testosterone replacement. 0 Patient did fine with thyroxine, glucocorticoid and testosterone replacement.
369 Mass reduction and hormone replacement Surgery More than two hormones Headache disappeared after surgery. Energy level improved. She developed diabetes insipidus after surgery. Patient required replacement therapy with corticosteroid, thyroxine, growth hormone, estrogen and desmopressin. 1 Headache disappeared after surgery. Energy level improved. She developed diabetes insipidus after surgery. Patient required replacement therapy with corticosteroid, thyroxine, growth hormone, estrogen and desmopressin.
354 Mass reduction Radiotherapy None or not specified Patient developed post-surgery diabetes insipidus, corrected with vasopressin. One year after surgery, MRI showed and enlargement of the residual suprasellar tumor. Patient underwent a second surgery (right frontal craniotomy) with subtotal tumor resection. Histology was identical to the first one. This surgery had several complications that required multiple corrective surgeries. Six years after the first operation, MRI showed that the residual tumor had increased from 10 to 12 mm in its greatest diameter, compressing the optic chiasm. Patient received radiotherapy (2,400 cGy). 6 months later MRI showed reduction in size. 0 Patient developed post-surgery diabetes insipidus, corrected with vasopressin. One year after surgery, MRI showed and enlargement of the residual suprasellar tumor. Patient underwent a second surgery (right frontal craniotomy) with subtotal tumor resection. Histology was identical to the first one. This surgery had several complications that required multiple corrective surgeries. Six years after the first operation, MRI showed that the residual tumor had increased from 10 to 12 mm in its greatest diameter, compressing the optic chiasm. Patient received radiotherapy (2,400 cGy). 6 months later MRI showed reduction in size.
355 Mass reduction and hormone replacement Radiotherapy Glucocorticoids and thyroixine (or other two hormone combination) Headaches were difficult to controlled with high dose prednisone. Patients developed iatrogenic Cushing's syndrome. 8 months later MRI showed enlargement of the pituitary stalk, with evidence of optic chiasm compression. Patient received radiotherapy (2,400 cGy). 3 months later the size of the tumor had reduced minimally but headaches disappeared. Patient still required hormone replacement. 1 Headaches were difficult to controlled with high dose prednisone. Patients developed iatrogenic Cushing's syndrome. 8 months later MRI showed enlargement of the pituitary stalk, with evidence of optic chiasm compression. Patient received radiotherapy (2,400 cGy). 3 months later the size of the tumor had reduced minimally but headaches disappeared. Patient still required hormone replacement.
7 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
288 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
22 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
4 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
5 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
6 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
12 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
8 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
9 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
3 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
59 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
15 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
26 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
149 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
1 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
316 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
2 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
179 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
27 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
148 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
87 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
30 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death during labor. Death during labor.
211 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
325 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death
120 Not applicable (autopsy) Not applicable (autopsy) Not applicable (autopsy) Death Death